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ABSTRACT 
 
HIV has become one of the biggest health problems up to date. After 30 
years of tremendous effort, the development of an HIV vaccine is still far from 
achieved. One of the main issues is the high mutation rate of the virus which 
results in the selection of mutated variants. This gives the virus the ability to 
escape from selective pressures, such as the immune system. Also the correlates 
for an effective immune response against HIV remain uncertain.  
T cells have been proven to play a key role in controlling the virus in HIV 
infected individuals. T cells recognize small fragments of HIV as antigenic 
peptides bound and presented on HLA molecules. The HLA molecules are the 
most polymorphic proteins in the entire human genome. As the HLA-peptide 
interaction is highly specific, HIV infected individuals will present different 
peptides from the HIV proteins dependent on their HLA repertoire. In this thesis 
we explore the complexity of functional HIV-specific T cell responses and global 
virus-host genetic variability in different study cohorts.  
Individuals with frequent exposure to HIV without establishment of 
infection have been well studied in the hope of finding the secret of their reduced 
susceptibility. However, no one has studied if exposure to HIV through oral sex 
can induce T cell responses. Through access to samples from healthy HIV 
negative individuals living in a relationship with an HIV infected partner we show 
that oral exposure is enough to mount a systemic HIV specific CD4+ and CD8+ T 
cell response.  
To cope with the enormous variability of HIV sequences and HLA alleles 
we combined the use of bioinformatic tools with molecular biology, and 
immunological assays. We successfully identified several highly immunogenic 
peptides that were recognized in a diverse study population infected with several 
HIV subtypes. Responses against these peptides were further investigated to 
address the effects of HIV point mutations on T cell recognition. We show that 
recognition of the HLA-peptide complex by the T cell receptor is highly sensitive 
and that one single point mutation will reduce the chance of inducing a response 
by 40%.  
Despite the high mutation rate of HIV, there are some regions that are 
more conserved within the HIV genome. Mutations in these regions have the 
potential of reducing viral fitness, why viral variant carrying such mutations may 
be less pathogenic. We hypothesized that the character of the HIV peptide (i.e. 
variable or conserved) targeted by CD8+ T cells would influence the quality and 
quantity of T cell responses, and affect disease progression. We show that 
patients targeting a conserved peptide in early HIV infection maintain their 
responses for up to four years, while patients targeting a variable peptide lose 
their responses over time. Importantly, patients targeting a conserved peptide 
had a lower viral load and a slower CD4+ T cell decline. The identification of 
virological and immunological characteristics that influences disease outcome is 
highly relevant for the development of a therapeutic vaccine.  
These studies are based on the access to exclusive patient material through 
excellent collaborations, and combination of bioinformatics and immunological 
assays. This thesis has brought new knowledge to the field, but also addressed the 
complexity of HIV specific T cell responses.   
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1. AIMS 
 
 
The overall aims of this thesis were to gain a deeper insight into functional T cell 
responses during early and chronic HIV infection and the complexity of the virus-
host interactions. 
 
Paper I:  To investigate if oral exposure is enough to induce a systemic HIV 
specific T cell response in HIV exposed uninfected individuals living 
with an HIV infected partner.  
 
Paper II:  To identify broadly immunogenic epitopes in an ethnically diverse HIV 
infected population infected with multiple HIV subtypes.  
 
Paper III: To explore the determinants for recognition of the virus and virus 
variants by epitope-specific CD8+ T cell responses based on the patients 
HLA genotype and autologous virus sequence quantitatively.  
 
Paper IV: To investigate whether the character of the immunodominant epitope 
(variable or conserved) targeted early in HIV infection influences the 
efficacy of the T cell responses over time and thereby the disease 
outcome 
   1 
2. Human Immunodeficiency Virus - HIV 
2.1 An Introduction to HIV  
Infection with the human immunodeficiency virus (HIV) has become one of the 
biggest health problems up to date. Around 35 million people are living with HIV 
today and it has been estimated that more than 25 million individuals have died 
from AIDS (UNAIDS, AIDS epidemic update 2010, www.unaids.org). The number 
of people suffering from and affected by the disease are even higher. This 
tragedy has demolished entire societies and severely affected family members 
emotionally as well as financially. Even though HIV is a global problem with a 
worldwide spread, the distribution is highly unfair. Countries and regions with 
extreme poverty have in general been the most affected, with the highest 
prevalence found in sub-Saharan Africa.  
 
2.2 The History of HIV 
It all started about 30 years ago when clinicians in New York and California 
reported an increased prevalence of different opportunistic diseases and some 
rare forms of cancer, such as Kaposi´s sarcoma, which typically is not seen in 
healthy individuals [1,2,3]. The observations were first made in young 
homosexual men, but soon such symptoms were also noted among intravenous 
drug users (IDU) and hemophiliacs. The disease was given the name acquired 
immunodeficiency syndrome – AIDS [4]. In 1983, Dr’s Francoise Barre-Sinoussi 
and Luc Montagnier at the Pasteur Institute in Paris managed to isolate the virus 
causing AIDS [5]. Shortly thereafter Dr Robert Gallo confirmed these findings [6], 
and the virus was given the name human immunodeficiency virus (HIV). In 
1986, a closely related virus was isolated in West Africa, and was named HIV-2 
[7,8]. The pathogenesis of HIV-2 is not as aggressive as that of HIV-1 and the 
spread has not been as successful. The virus is mainly found in West Africa with 
the highest prevalence in Guinea-Bissau [9].  
 
2.3 The Origin of HIV 
Phylogenetic studies show that HIV has been introduced into the human 
population several times, and the spread of the pandemic we are suffering from 
today probably started about 100 years ago [10,11,12]. HIV originates from the 
simian immunodeficiency virus (SIV) that is found in non-human primates [13]. 
HIV-1 most likely originates from SIV in chimpanzees (Pan troglodytes 
troglodytes) [14] while HIV-2 is more closely related to SIV in sooty mangabey 
monkeys (Cercocebus atys) [15]. HIV-1 is divided into groups M (major group), O 
(outlier) and N (non-M/non-O) [16]. Recently a new group, P, was identified [17]  
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                         Figure 1 
                         The genome organization and virion structure of HIV-1. 
 
 
 
that is more closely related to SIV found in wild-living gorillas (Gorilla gorilla) 
[17,18:Van Heuverswyn, 2006 #19]. The M group is further divided into 
subtypes A, B, C, D, F, G, H, J, K as well as several circulating recombinant forms 
(CRFs) between different subtypes [19]. Up to date more than 40 CRFs have 
been identified (www.hiv.lanl.gov). 
 
2.4 HIV-1 Structure and Protein Functions 
HIV is a lentivirus belonging to the retrovirus family (Retroviridae). Retroviruses 
are enveloped with an RNA genome. The most distinguishing features for 
retroviruses are their replication through a DNA intermediate, which is 
transcribed from RNA with the help of the viral enzyme reverse transcriptase, 
and the integration of the viral genome into the host cell DNA. This integration 
leads to the establishment of a lifelong chronic infection. Newly produced viral 
RNA copies and proteins move to the surface of the cells to form new HIV 
particles. The immature viral particles bud from the cellular membrane and then 
mature by cleavage of the viral polypeptides by protease. 
HIV is a single stranded positive RNA virus with a spherical envelope, a matrix 
and a cone shaped capsid proteins, containing the two RNA strains. The HIV 
genome is about 10 000 nucleotides long and encode nine genes: gag, pol, env, 
rev, nef, tat, vif, vpr and vpu. By alternative splicing and protein degradation, HIV 
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transcribes fifteen proteins in total; Gag-p6, Gag-p7, Gag-p17, Gag-p24, Pol-
reverse transcriptase (RT), Pol-integrase, Pol-protease, Env-gp120,Env- gp41, 
Rev, Nef, Tat, Vif, Vpr, and Vpu.  
The HIV envelope consists of a lipid bilayer acquired from the cell membrane 
during budding and the Env proteins gp120 and gp 41, forming the spike and 
knob structure respectively. The Env protein gp 41 is a transmembrane 
glycoprotein, while the gp120 protein forms an extracellular trimer, 
noncovalently bound to the extracellular part of gp41. Binding of the Env 
proteins to receptors on the cell surface of the host cell leads to docking of the 
viral particle and fusion with the cell membrane. Initially, the gp120 binds to the 
CD4 receptor on immune cells. This interaction leads to conformational changes 
of gp41 and exposes the binding site for the co-receptors, most commonly CCR5 
and CXCR4. 
The gag gene encodes the precursor protein Gag p55. This protein is further 
cleaved into four structural proteins; the capsid protein Gag p24, the matrix 
protein Gag p17, the nucleocapsid Gag p7, and the spacer peptide 2 Gag p6. The 
p7 and p6 proteins are located inside the capsid to protect the viral RNA.  
The pol gene encodes for three enzymes that are crucial for an efficient 
reproduction of the virus: a protease, a reverse transcriptase (RT), and an 
integrase. The RT transcribes the viral RNA to a DNA intermediate, the integrase 
enable integration of the viral DNA into the host genome, and the protease 
cleaves Gag-Pol precursor proteins into functional proteins enabling the 
maturation of the viral particle. Once the viral genome has been integrated it is 
referred to as provirus. Inside infected host cell in a resting state the integrated 
DNA can be silent and latently embedded for years before the cell is activated 
and the viral proteins are translated by the host cell machinery.  
HIV also encodes the regulatory proteins; Tat, Rev and Nef. Tat is a trans-
activator and facilitates initiation and elongation during HIV transcription. It 
binds to Tat responsive regions (TAR) in the long terminal repeats (LTRs) of the 
pro-viral DNA and allows for the transport of the unspliced messenger RNA 
(mRNA) from the nucleus to the cytoplasm. Rev is a protein that stabilizes and 
facilitates this transportation. Nef is one of the proteins that are expressed 
earliest during primary HIV infection. This protein has several important 
functions such as down regulation of CD80/86 and MHC class I and II molecules. 
This down-regulation inhibits recognition of HIV infected cells by other immune 
cells. Nef also down-regulates the CD4 molecule, which facilitates the release of 
progeny virus. The HIV genome also encodes three small accessory proteins, 
Vpu, Vpr and Vif. Vpu degrades CD4 and enhances the release of new virus 
particles. Vpr is a trans-activator for host cellular genes and promotes cellular 
differentiation. Vif prevents the action of the cellular antiviral defense protein  
. 
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APOBEC-3G, which promotes the infectivity of the virus [20]. Detailed 
information of the HIV proteins and their functions can be found at: 
www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html 
 
 
 
 
 
  Figure 2 
  The life cycle of HIV: 
1. Viral attachment through binding of the viral spike protein to the host  
cell receptors. The attachment to the CD4 receptor induces conformational  
changes in the viral envelope proteins allowing binding to the co-receptor 
2. Fusion with host cell membrane and viral entry 
3. Uncoating 
4. Reverse transcription of the viral RNA to DNA by the viral enzyme RT  
5. Nuclear import of the viral DNA 
6. Integration of the viral DNA into the host genome, facilitated by the 
 viral enzyme integrase 
7. Transcription of viral mRNA from the integrated DNA 
8. Translation of the viral proteins 
9. Virion assembly at the cell surface 
10. Budding and release of newly formed virion. Maturation through  
cleavage of the Gag-Pol precursor proteins 
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2.5 Genetic Diversity 
One of the characteristics of HIV is the large population size and the high 
production of progeny virus. There are about 108 productively infected cells 
within an HIV infected individual, and about 1010 new virions are produced 
every day [21,22]. This fast reproduction together with an enormously high 
mutation rate makes HIV exceptionally diverse. This high genetic diversity is 
seen not only at a population level but also within the patients. Estimation shows 
that the average mutation rate for HIV is 0.1-0.3 mutations per genome and 
replication cycle [23,24]. In comparison, despite that the influenza virus has a 
high mutation rate, the viral population found within one chronically infected 
HIV individual at one time point is as diverse as the influenza variability seen 
worldwide during a flu season [25]. The successful diversity is mainly due to the 
RT enzyme, which is error-prone and lacks proof reading ability, thus causing a 
high proportion of point mutations during the transcription of RNA to DNA. 
These mutations may be substitutions, insertions and/or deletions of 
nucleotides. Secondly, RT jumps between the two HIV RNA strands during the 
transcription and gives rise to a DNA template that is a recombination of two 
parental RNA strains [26]. Thirdly, the cellular enzyme polymerase II used 
during translation of the integrated viral DNA also lacks a proof reading function. 
Fourthly, there are other factors, such as the cellular antiviral proteins APOBEC. 
The APOBEC proteins are cellular enzymes that induces nucleotide 
hypermutations during reverse transcription, which can destroy the replicative 
capacity of the virus and contributes to the variability of HIV [27].  
The high diversity of HIV is a major challenge for the immune system as well as 
for the development of HIV vaccines, as the virus tends to mutate and escape 
under selective pressure. Selective pressure from the immune system is a strong 
driving force in HIV evolution.  
 
3. Immunology 
The immune system is highly sophisticated and advanced with several 
alternative ways to combat invading pathogens such as viruses, bacteria and 
fungi. There are physiological barriers, such as the skin, which is made up by 
epithelial cells, and mucosal membranes, which cover the respiratory, 
gastrointestinal, and genital tracts. There are also chemical barriers, e.g. low pH, 
that act to create an unpleasant milieu for invading pathogens. Also cells of the 
immune system and soluble factors produced by cells play a key role in our 
defense against pathogens. The immune system can be divided into two different 
systems acting in different manners: the innate immune system and the adaptive 
immune system. Although they differ significantly from each other, there are a 
lot of interactions between them, and they are to some extent dependent on each 
other.  
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3.1 The Innate Immune System 
The innate immune system is the first defense against pathogens, and acts within 
a couple of hours after an infection. It is referred to as the unspecific immune 
response, and recognizes conserved patterns on pathogens and damaged cells. 
Activation of the innate immune system by recognition leads to a cascade of 
events. Among the most important players are the dendritic cells (DC). DCs 
circulate in the peripheral blood and secondary lymphoid tissue, as well as in 
mucosa and other organs. DCs are professional antigen presenting cell (APC) 
that engulf and digest pathogens and cellular debris of infected cells or cancer 
cells though phagocytosis. When a DC captures an antigen, it becomes activated 
and homes to a lymph node. The digested antigens are presented as short 
peptides on major histocompatibility complex (MHC) molecules for recognition 
and activation of other immune cells, including naïve T cells. Other professional 
APCs are B cells and macrophages. Neutrophils, basophils, and eosinophils are 
granulocytes with the ability to phagocytose. However, they cannot present 
antigens as the APCs, but they are important players in the innate immune 
system since they engulf pathogens and can release soluble factors, such as 
histamine, which is produced by basophils and triggers the inflammatory 
response. Natural killer (NK) cells recognize and kill infected cells and tumor 
cells through lysis. Recognition can be either direct, via recognition of 
activation/inhibition receptor expression, or due to antibody-coating of the 
damaged cell or invading pathogens. NKT cells express features of both T cells 
and NK cells, and they can recognize glycolipids presented on the CD1d 
molecules that are expressed on APCs.  
Other important factors for the lytic clearance of damaged cells are the 
complement system, and secreted soluble factors like the anti-microbial peptides 
(AMP). The α- and β-defensins are important AMPs that are positively charged 
and can bind to the negatively charged membrane of microbes and thereby cause 
lysis [28,29]. The innate immune system recognizes damage-associated molecular 
patterns (DAMP) in cancer cells, as well as pathogen-associated molecular 
patterns (PAMP), e.g. proteins, DNA, RNA, and sugar motifs. The most important 
pathogen recognition receptors (PRRs) are the toll-like receptors (TLRs), which 
are expressed both intracellular and on the cell surface. Upon recognition, 
activation occurs and sets the immune system into a viral state by production of 
interferons (IFN), which can be secreted by DCs among other cell types. The most 
important role of IFNs is acting as communicators between different cells. They 
induce up regulation of MHC molecule expression, which is important for the 
adaptive immune system. IFNs also increase protein kinase expression, such as 
APOBEC, which is an important protease used in the defense against viral 
infection. Infection also creates an inflammatory state that will lead to the release  
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of chemokines such as MIP1 , MIP1  and RANTES. Chemokines recruit other 
immune cells to the site of injury or infection.  
 
3.2 The Adaptive Immune System 
The adaptive immune system is highly specific and takes a longer time to react 
and mature than the innate immune system. This maturation process can take 
days or even weeks. There are two arms of the adaptive immune system; the 
cellular and the humoral responses. The cellular immune system is made up by T 
cells while the humoral immune system is built up by B cells. T and B cells both 
originate from the same haematopoietic stem cells in the bone marrow but 
mature at different sites. The T cells mature in the thymus while the B cells have 
their development in the bone marrow. T and B cells express antigen-specific 
receptors called T cell receptors (TCR) and B cell receptors (BCR). Upon 
encounter with the proper antigen, both B and T cells start to proliferate rapidly. 
This clonal expansion of antigen-specific cells is essential to enable control and 
depletion of the incoming pathogen. T cells are further divided into CD4+ T cells, 
CD8+ T cells, and NKT cells. 
 
3.2.1 The Cellular Immune Response 
3.2.1.1 Activation of cellular immune responses 
The T receptor on the T cells recognizes antigenic peptides, so called epitopes 
(short fragments of a partly degraded antigen) presented on MHC molecules on 
APCs. This recognition is highly specific and is dependent on binding to both the 
MHC molecule and the epitope. The T cells undergo clonal selection including a 
positive and a negative selection during their maturation in the thymus to 
ensure that the cells can distinguish self from non-self antigens and not to react 
against self molecules as they proceed into the circulation. During the positive 
selection, T cells will have to interact with several cell surface molecules such as 
MHC molecules, to ensure reactivity and specificity. Cells that are incapable of 
binding will proceed into programmed cell death, i.e. apoptosis, while cells that 
express a TCR with a binding capacity will move on to the negative selection. In 
the negative selection process, the cells will be eliminated if they bind to strongly 
to the self antigen-MHC complex. There is a delicate threshold between a too 
week and a too strong binder. Errors in this selection can cause autoimmune 
responses due to recognition of self-antigens in the tissues. 
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3.2.1.2 Antigen binding and presentation 
Antigens are presented to the TCR on MHC class I and MHC class II molecules. 
MHC class I molecules are expressed on all nucleated cells, and present 
intracellular antigens such as viruses. These antigens have been degraded in the 
cytoplasm by the proteasome into optimally 8-11 amino acid long epitopes. They 
are transported from the cytoplasm into the endoplasmic reticulum (ER) via the 
transporter associated with antigen processing (TAP) proteins, where the 
epitopes are loaded on to a MHC class I molecule. The MHC epitope complex is 
transported to the cell surface via the Golgi complex.  
 
 
   Figure 3 
   Antigenic processing and presentation by MHC class I (A-E) and class II (1-7) molecules. 
A. Degradation of endogenous antigens into peptides by the proteasome 
B. Transportation of peptides into ER via TAP proteins 
C. Loading of antigen on to the MHC class I molecule in the ER 
D. Transportation of MHC class I-peptide complex to cell surface via the Golgi complex 
E. Presentation of endogenous antigen to CD8+ T cells  
 
1. Exogenous antigen is taken up by phagocytosis 
2. Exogenous antigen is degraded within lysosome vesicle 
3. MHC class II molecule associated with an invariant chain is transported from ER  
to the Golgi complex 
4. Invariant chain is degraded within the endosome 
5. Fusion of the late endosome and lysosome. Loading of the exogenous antigen  
on to the MHC class II molecule 
6. Transportation of MHC class II-peptide complex to the cell surface 
7. Presentation of exogenous antigen to CD4+ T cells 
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MHC class II molecules are expressed on professional APCs such as DCs, 
macrophages and B cells. They present exogenously derived antigens that have 
been phagocytoced by the APCs. The phagosomes fuse with lysosomes where the 
phagocytosed antigen is degraded into short peptides (usually 11-20 amino 
acids). The lysosomes fuse with endosomes containing MHC class II molecules, 
and the MHC epitope complex is transported and presented on the cell surface. 
In humans the MHC is encoded by genes called human leukocyte antigen (HLA). 
The HLA class I and II alleles are the most variable genes in the human genome. 
The HLA class I antigens are further divided into A, B, and C alleles. There are 
more than 480 HLA-A, 800 HLA-B and 260 HLA-C alleles described in the HLA-
database (http://www.ebi.ac.uk/imgt/hla). Each individual has the ability to 
present three to six different HLA class I alleles. The number of different alleles 
in each person depends on whether the individual is homozygote or 
heterozygote at each locus. Different HLA alleles have different binding 
specificities, i.e. depending on what alleles are represented, individuals will 
respond against different epitopes from the same pathogen. A heterozygote will 
have an advantage in most infections, since they are able to present a broader 
variety of antigens compared to individuals with a homozygote HLA allele 
composition. However, even if the same epitope is presented on several different 
HLA alleles [30], the impact on the pathogen might differ in the different 
individuals, depending on which allele that presents the antigen [31].  
 
3.2.1.3 CD4+ T cells  
The CD4+ T cells are called T helper (Th) cells. They secrete cytokines and 
express co-stimulatory molecules that promote differentiation and maturation of 
other immune cells after recognition of exogenously processed antigens 
presented on MHC class II molecules. There are several different types of T 
helper cells, based on different cytokine secretion profiles upon activation and 
their expression of intra- and extra-cellular molecules. The identification of 
CD4+ T cell subsets is a complicated topic and new subsets are emerging as the 
identification of cytokine production and cellular markers progresses. The Th1 
subset produces IFN  and TNF and plays the bigger role in the control of 
intracellular pathogens. The Th1 subset is potent producers of IL2, which is a 
cytokine that facilitates the proliferation of T cells, and promotes the activation 
and differentiation of CD8+ T cells. The Th2 subset produces IL4, IL5, IL6 and 
IL13, which are cytokines that facilitate the priming of the humoral response, 
and are more involved in the clearance of extracellular pathogens. Th17 cells are 
a subset of IL17 producing cells. Similarly to the Th2 cells, the Th17 cells also act 
on certain extracellular pathogens, but it has been shown that Th17 cells are also 
involved in autoimmune diseases and tissue inflammation [32]. Another subset 
of CD4+ T cells is the regulatory T cells (Treg). These cells are highly important 
for the maintenance and control of the adaptive immune system. Tregs are also 
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involved in tolerance, prevention of autoimmune diseases and limit chronic 
inflammatory diseases (reviewed in [33]). There are some additional subsets of 
CD4+ T cells, such as Th22 and Th9, which are reviewed in [34]. 
 
Figure 4 
Overlapping HLA class I epitopes within a short fragment of the HV Gag p17 protein, illustrated 
by the amino acid sequence of the HXB2 strain. The epitopes are restricted to different HLA class 
I alleles (given within parenthesis). This shows how one sequence can contain several different 
HLA restricted epitopes, hence how the same protein can be presented differently dependent on 
the HLA allele. 
 
 
3.2.1.4 CD8+ T cells  
The CD8+ T cells recognize intracellular antigens presented on MHC class I 
molecules. Studies have shown that the CD8+ T cells are highly important in the 
control of the virus in HIV-infection in both humans [35, Borrow, 1994 #40] and 
in non-human primates [36,37,38]. Activated CD8+ T cells that can kill infected 
cells are called cytotoxic T cells (CTL) and they produce antiviral cytokines. 
To become activated by professional APCs, the CD8+ T cells need three signals. 
First its TCR will recognize and bind to the proper MHC epitope complex. The 
second signal is obtained through co-stimulatory molecules, such as CD28 on T 
cells, interacting with CD80/86 on the DCs. Thirdly; cytokines are needed to 
facilitate differentiation and proliferation of the antigen-specific CD8+ T cells. 
Once the T cell is activated it circulates to peripheral tissues, where it can 
recognize and kill cells containing the same antigen that they were introduced to 
by the DCs. Upon recognition and activation, there will be a polarization of lytic 
granules in the CTLs to the contact site with the damaged cell, resulting in the 
formation of the immunological synapse. The CTL will release the contents of the 
granules, including perforin and granzymes which will act on the targeted cell 
and induce apoptosis [39,40]. Perforin is harmless within the granules, but 
undergoes a conformational change once it is released. It creates circular pores 
in the cell membrane of the targeted cell or mediate endocytosis enabling 
granzyme B to enter the target cell [41]. Granzyme A and B are proteases that 
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cleave several proteins in the cytoplasm. The released the granular contents will 
act directly on the damaged cell and induce apoptosis, but the CTL also acts 
indirectly by cytokine signaling. The anti-viral cytokine IFN  has several 
important features. It affects the virus and blocks viral replication upon 
secretion. IFN  also acts on other immune cells and facilitates activation of 
macrophages and NK cells, and promotes isotype switching in B cells. Moreover, 
IFN  up-regulates the MHC molecules on infected cells, which leads to a more 
efficient antigen presentation. Apoptosis may also be induced in damaged cells is 
via CD95 (Fas), which is expressed on a variety of cells upon injury. Both CTLs 
and NK cells express the Fas ligand and bind to Fas on damaged cells, thereby 
inducing apoptosis.  
As mentioned, CD8+ T cells recognize intracellular antigens presented on MHC 
class I molecules. The DCs have the ability to present exogenous antigens on the 
same molecules, a phenomenon called cross-presentation, which leads to cross-
priming and allows CD8+ T cells to also recognize exogenous antigens [42]. 
It is known that the recognition of antigens by the TCR is highly specific, but 
some cross-recognition does occur. Thus, antigens that are very similar but not 
identical can in some cases be recognized by the same TCR. This can be of 
advantage for the immune system when it comes to pathogens with high 
mutation rates, such as HIV, that adopt under selective pressure (notably by 
mutations within the amino acid sequence) in order to escape the immune 
system. However, the promiscuity of the TCR recognition can lead to 
autoimmune disease when a self-antigen is similar to that of a pathogen, and the 
immune response starts attacking healthy cells expressing those self-antigens 
[43].   
 
3.2.2 The Humoral Immune Response 
The humoral immune response is mediated by B cells. The B cells express an 
antigen binding receptor, the B cell receptor. This recognition of the antigen by 
the B cell receptor is highly specific. It recognizes both whole proteins, which are 
found directly on the pathogen surface or as free soluble antigens in the 
circulation. Secretion of cytokines from the T helper cells, as well as binding of 
the B cell receptor to the antigen, activates the B cell and induces differentiation 
into plasma cells. The plasma cells produce soluble antibodies, which are free 
forms of B cell receptors. There are several ways for B cells to use the antibodies 
for elimination of a pathogen. Coating the pathogen with antibodies allows for 
other immune cells to bind to the Fc part of the antibody and phagocytose, or 
lyse the pathogen. The antibodies can also neutralize the pathogen by binding to 
a site used by the pathogen to dock with a target cell, thereby inhibiting infection 
by the pathogen.    
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4. HIV Infection 
4.1 HIV Transmission  
The most common route for HIV transmission is via heterosexual intercourse. 
The virus can enter the body through the mucosa in the genital, rectal and oral 
tracts. HIV is also transmitted via blood through blood transfusion, organ 
transplantation, needle exchange among intravenous drug users, and needle 
accidents in health care and laboratory settings. HIV can also be transmitted 
horizontally from mother-to-child during delivery and breast-feeding. The risk 
of transmission differs depending on the transmission route, the presence of 
other infections, and the level of viral load exposure. Genital exposure 
constitutes a considerably lower transmission risk compared to rectal exposure. 
However, in the presence of other genital infections, HIV may enter more easily 
through lesions in the mucosa, which increases the risk for infection. Also the 
level of viral load during exposure makes a difference in the transmission rate as 
a higher viral load equals a higher risk for infection [44].  
Upon exposure, HIV infects target cells via lesions in the mucosa, via transcytosis 
in the epithelial cells, or directly at the infection site. The virus can also dock on 
DCs without infecting the cells by binding to DC-SIGN, and then be transported 
to lymph nodes where it encounters and infects other target cells. The virus uses 
the CD4 receptor as the main receptor and the chemokine receptors CCR5 or 
CXCR4 as co-receptors for docking and fusing with the host cell. There are other 
cells, like DCs, macrophages and microglia in the brain that also express these 
receptors and may become infected. HIV preferentially targets activated CD4+ T 
cells [45] and the loss of these cells leads to immunodeficiency and the 
emergence of opportunistic diseases. These features constitute the hallmark of 
disease progression and the onset of AIDS. 
 
4.2 Disease progression in HIV infection 
During the acute stage of infection the viral load reaches a peak level and there is 
a massive destruction of CD4+ T cells [46,47]. The most severe loss of T cells is in 
the gut associated lymphoid tissue (GALT), where around 80% of the CD4+ T 
cells are depleted [48,49]. Within a couple of weeks, the adaptive immune 
response increases, the peak viremia drops to a steady state level [50], and the 
CD4+ T cell count recovers to some extent. The HIV-specific CTL responses play 
an important role in viral control [35, Borrow, 1994 #40,36,37,38]. The level of 
viral load at the peak and during steady state is a good predictor of disease 
progression, i.e. that a low viral load predicts a better disease outcome with a 
slower progression [44]. Many individuals experience flu-like symptoms at this 
first acute phase [51]. 
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After the acute infection and a stabilization of the viral load, HIV infected 
individuals enter a chronic phase that can last for years. During this time, the 
immune system may partially control the virus but it is not able to clear the 
infection, due to several factors such as the integration of the viral genome into 
the host cell DNA, and the high reproduction rate of the virus. During the chronic 
infection there is a constant depletion of CD4+ T cells throughout the course. 
This imbalance in the immune cell distribution dampers several other immune 
cells and leads to an impairment of the immune response. Also, during the 
chronic phase the immune system is constantly activated due to the ongoing 
viral replication, which eventually will lead to exhaustion and a defect 
responsiveness of the immune cells [52]. 
If left untreated, the chronic phase most commonly last for seven to ten years. 
Once the CD4+ T cell count is too low, and the patient starts to suffer from 
several opportunistic diseases, such as rare cancer forms like Kaposi´s sarcoma 
and different herpes virus infections. These are diseases that a healthy immune 
system normally combats, but at this severe stage of the HIV infection the 
immune system is too hampered and inefficient. Ultimately, the CD4+ T cell 
count drops below 200 cells per l, and the patients develop opportunistic 
diseases and AIDS. Without treatment the patient will eventually die from these 
AIDS related infections.  
 
 
Figure 5 
The clinical course of HIV infection. 
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5. Potentials for a Prophylactic or Protective HIV 
vaccine 
5.1 Exposed uninfected individuals 
Some individuals are less susceptible to HIV infection, and are referred to as 
exposed uninfected individual (EUI). The first report describing this 
phenomenon was published in 1989 [53]. Since then there have been numerous 
observations of individuals that are exposed to HIV without getting infected. 
These individuals have been found among homo- and heterosexual discordant 
couples [54,55,56], commercial sex workers [57], and children born to HIV 
positive mothers [58]. EUIs have been intensely studied in the hope of 
identifying factors associated with protection. Such knowledge might be 
applicable in clinical settings and contribute to the discovery of a protective 
immune response needed for development of an effective vaccine.  
Despite the large number of studies on EUIs, there is no single factor that applies 
to all. There have been reports showing elevated levels of soluble factors such as 
RANTES [59,60] and alpha defensins [61,62] in EUIs. Also genetical [61,63] and 
immunological factors related to the cellular [64,65,66,67], and humoral 
immune responses [68,69] have been identified (reviewed in [70]). Several 
studies have shown neutralization of HIV with antibodies of unknown specificity 
[56,68,69,71]. HIV specific T cell responses have been found in EUIs although 
they remain seronegative. Also, some HLA alleles are seen at a higher frequency 
in EUIs compared to HIV infected individuals [72]. Interestingly, Kaul et al show 
that the targeted T cell epitopes differed in the EUI group compared to the HIV 
infected individuals, while they expressed identical HLA alleles [73]. Adaptive 
immune responses towards the HLA molecules of the partner, targeting allo-
antigens have also been detected since these molecules are expressed on the 
surface of the virus [54,55]. We showed in paper I in this thesis that HIV 
exposure via oral sex is enough to mount a systemic HIV specific T cell response 
in exposed uninfected partners of discordant couples [74]. The development of 
HIV specific immune responses in these EUIs indicates that their immune system 
has recognized viral particles but that the virus has not been able to establish an 
infection.   
Among these different observations in EUI studies, there is only one factor that is 
clear and solid when it comes to reduced susceptibility, and that is the delta 32 
mutation in the CCR5 gene [75]. Individuals with two copies of the CCR5 delta 32 
mutation are almost completely protected against sexual transmission of HIV 
[76], and even those with one copy of the mutation (i.e. heterozygous) do have 
some partial protection against infection [77]. This mutation is more common in 
the western parts of the world with the highest prevalence in the Nordic 
countries, where the mutation (homo- and heterozygote) is found in up to 14% 
of the population, and homozygotes in 1-2.5% [78].  
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Another factor that has been proven to strongly decrease the risk for HIV 
transmission is male circumcision. Studies have shown that circumcised male 
has a reduced susceptibility to HIV transmission with more than 50 % compared 
to uncircumcised men [79,80]. 
 
5.2 Factors associated with disease progression 
Although clearance of the virus in an HIV infected individual is not achievable, 
there are differences as to the level of viral replication and speed of the disease 
progression (reviewed in [81]). Certain individuals, i.e. elite controllers and 
long-term nonprogressors (LTNP), are able to control the infection and have a 
slow disease progression. These controllers manage to keep the viral load below 
detectable levels (<50 copies/ml) and can be infected for decades with sustained 
CD4+ T cell counts [81,82,83]. Identifying viral characteristics and 
immunological and/or genetic factors that are responsible for the enhanced 
control in these populations have been intensely studied. Several immunological 
factors have been associated with disease progression. Some of the most 
important findings are highlighted and discussed in this section.  
As described in the previous section, CCR5 is the co-receptor that HIV uses for 
viral binding and fusion to the host cell. The CCR5 delta 32 mutation results in a 
truncated form of CCR5, which prevents virus attachment. Homozygotes for the 
CCR5 delta 32 mutation (inherited from both parents) are protected against 
sexual transmission of HIV whereas heterozygote’s only have a partial 
protection. However, during an HIV infection heterozygous for the mutations 
have a lower viral load and a slower disease progression due to the truncated co-
receptor expression which inhibits the viral biding and fusion with new cells 
[77]. 
It is well known that the CD8+ T cells play a key role in the control of viral 
replication in acute [35,84], and chronic infection [85,86]. It has also been shown 
that certain HLA class I molecules presenting the antigens for CD8+ T cells are 
important for disease progression [87]. Being homozygous for the HLA-A, -B, 
and/or C alleles is a disadvantage, while heterozygous individuals have an 
advantage in terms of disease progression [88,89]. A diversity of HLA alleles 
gives more options for antigen presentation and is better for targeting the 
pathogen from several angles. Some alleles, such as HLA-B57/58, and HLA-B27, 
are more frequently found in slow progressors [90,91,92], while HLA-B35 has 
been found at a higher frequency in individuals with a more rapid disease 
progression [88,93,94]. The mechanism behind these associations seems to be 
highly delicate, and even minor amino acid differences between HLA alleles 
might break this association. Despite that only three amino acids differs in the 
genomic composition, HLA-B5801 is found at a higher frequency in subjects with 
slow disease progression, while HLA-B5802 does not have any association with 
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disease outcome [95]. Similarly, HLA-B3502 and B3503 are associated with 
faster disease progression while HLA-B3501 is not, even though there is only 
three and one amino acid difference between the two alleles, respectively 
[96,97].   
Kosmrlj et. al. found that individuals carrying protective HLA alleles had a larger 
fraction of naïve T cell clones recognizing viral epitopes and epitope-variants 
presented by these HLA alleles [98]. Several studies show that alleles, which are 
associated with better disease progression, are more prone to bind to epitopes 
located in the more conserved regions of the HIV proteome, such as the capsid 
protein Gag-p24 [99]. Regions that are more conserved among HIV subtypes and 
strains are crucial for the viral fitness, why escape mutations under 
immunological pressure are more difficult for the virus to cope with and are thus 
less likely to persist. Another observation is that epitopes targeted by alleles 
associated with better disease progression are similar to epitopes targeted by 
chimpanzees during SIV infection [100,101]. This is interesting since despite 
susceptibility to SIV infection and establishment of chronic infection, the 
chimpanzees do not develop AIDS.   
The character of the immunologically targeted epitopes is one of the most 
important factors in viral control. HIV infected individuals with a broad response 
targeting epitopes in the Gag region, which is more conserved, have a lower viral 
load compared to those who only target one or no Gag epitopes in chronic 
infection. The opposite phenomenon is seen for in the targeting of Env epitopes, 
which is a highly variable protein. HIV positive subjects with broad Env 
responses have a significantly higher viral load and lower CD4+ T cell count than 
subjects with few or no Env responses [102].  
In addition to the importance of epitope character, there have also been 
qualitative differences associated with progression. Patients with slow disease 
progression such as LTNP and individuals infected with HIV-2 have a higher 
fraction of polyfunctional T cells that are capable of producing multiple 
cytokines, such as MIP-1β, TNF, IL2 and IFNγ, at the same time upon stimulation 
[103,104,105]. This is in comparison to progressors who have more of a 
monofunctional T cell profile. Controllers also have a higher proliferative 
capacity [106]. The level of IL2 has been associated with the proliferative 
capacity of both CD4+ and CD8+ T cells [107]. There is also a higher frequency of 
cells producing perforin and granzyme B in controllers, which gives them a 
greater cytolytic ability [108,109]. Activation markers, such as CD38 and HLA-
DR are elevated in HIV infection and are found to correlate with disease 
progression [110,111]. Slow progressors have also been identified with lower 
levels of immune exhaustion compared to progressors [106,108,109,112,113]. 
However, it is not clear whether these qualitative differences are the cause or 
the effect of a better disease outcome and a more intact immune system. Antigen 
sensitivity seems to be involved in the protective role of polyfunctional T cell 
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responses [114,115]. A low viral load also means less exhaustion and damage of 
cells, while an impairment of the CD4+ T cell repertoire gives a less effective 
immune response. It is also known that when progressors are put on anti 
retroviral treatment (ART) they increase the CD4+ and CD8+ T cell functions, but 
this does not mean that they are able to control the viral replication once the 
treatment is withdrawn [116,117]. The increased number of functions  is rather 
a result of lowering the antigen exposure [117,118].  
 
5.3 The history and current goals for HIV vaccines 
Although 30 years has passed since the discovery of HIV, we still do not have a 
vaccine against the virus. Several vaccines against other pathogens are delivered 
as attenuated pathogens. However, vaccination with attenuated HIV is not 
possible due to the risk of reversion to an infectious virus particle that regains 
its pathological features. Therefore, most HIV vaccine candidates have been 
delivered either as recombinant soluble proteins in order to induce neutralizing 
antibodies (NAbs), or as HIV genes via viral DNA vectors to stimulate a T cell 
response. There have been several changes of focus in the HIV vaccine field 
during the years. Initially, the field was focusing on induction of NAbs to block 
viral entry into the host cell. Even though some success was seen in in vitro 
cultures against lab adapted HIV strains, the induced NAbs had no effect on 
primary HIV isolates [119]. Then, the importance of T cells for viral control in 
early infection was revealed [35, Borrow, 1994 #40,84] and combined with 
repeated failures in NAb protection, the field shifted towards T cell based 
vaccine candidates [120]. Today the field has switched again, and the current 
general belief is that an efficient HIV vaccine needs to be able to induce both 
humoral and cellular immune responses [121].  
The first approved HIV vaccine trial was executed in October in 1987 [122]. At 
this time, there was not enough insight about the complexity of this virus, and 
the field was rather optimistic to succeed. Since then the disappointments have 
been many, with more than 170 phase I or II clinical trials all over the world that 
all have failed to induce any protection against infection, nor lowered the viral 
load, or slow down the CD4 decline in HIV infected vaccinees 
[120,123,124,125,126]. In 2009, the world’s first positive results were presented 
after a phase IIb HIV vaccine trial performed in Thailand [127]. This was a 
randomized, multicenter, double-blinded, placebo-controlled efficacy trial, using 
a heterologous prime-boost approach. The subjects were primed with a 
recombinant canarypox vector vaccine (ALVAC-HIV [vCP1521]), and boosted 
twice with a recombinant glycoprotein 120 subunit vaccine (AIDSVAX B/E) 
administered through injections. This study showed a 31.2% reduction in the 
infection rate in vaccinated volunteers compared to the placebo group. The 
efficacy was higher during the first year post vaccination, but had a decreased 
efficacy over time. Also, due to numerous caveats and interpretation of the 
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results, it has been debated whether the reduction really is significant, and what 
the factors responsible for this potential protection could be. The biggest 
problem with the development of an HIV vaccine is the high mutation rate of the 
virus together with the genetic diversity of the immune system in humans 
[128,129]. How well the vaccine from the Thai trial would cope with the global 
diversity of HIV strains and the human HLA-variation is still not known.  
One solution to the problem of virus diversity might be the use of a mosaic 
vaccine. The mosaic construct was presented in 2007 by Fisher et al, and is an in 
silico optimization method for maximization of the coverage of potential T cell 
epitopes [130]. Since then, two vaccine trials have been published [131,132]. 
Both of them were performed in rhesus monkeys, with two different delivery 
strategies. Both studies showed promising results and induced responses of high 
broadness (i.e. number of targeted epitopes), and depth (i.e. subtype variants of 
the same epitope) without compromising the magnitude of the response. This 
approach has similarities to our study that was published in 2008, where we 
used an in silico method to identify broadly immunogenic peptides that would be 
recognized in individuals of different ethnical backgrounds infected with 
different HIV subtypes (paper II) [133]. We found that the vast majority of our 
identified elite epitopes were represented in the mosaic construct. The 
differences are that the mosaic construct is a whole protein approach that does 
not consider antigen presentation, while our method is focusing on identifying 
optimal epitopes to target, and address antigen presentation capacity by taking 
HLA-binding, proteosome cleaving, and TAP-transportation into account. Human 
trials of the mosaic vaccine are ongoing and it will be very interesting to see 
whether this novel strategy is superior for protection against HIV infection or 
not.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
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6. Results and discussion 
6.1 Introduction 
The main task of this thesis was to identify factors that influence the efficacy of an 
HIV-specific immune response directed by CD8 T+ cells. A better understanding of 
the complexity of the interaction between the immune response and the virus is 
important for the development of HIV vaccines. The main goal would be a 
prophylactic vaccine that could prevent new infections. There are some rare 
individuals who are naturally less susceptible and remain uninfected despite 
being repeatedly exposed to the virus. These EUI have been heavily studied in the 
hope of finding the key to their natural defense. One potential factor is through 
immune responses induced by repeated exposure to the virus. In paper I we 
studied the prevalence of anti-HIV cellular immune responses in a cohort of EUI 
who had been exposed through oral sex by their HIV infected partner.  
The main problem when it comes to the development of a vaccine or 
identifications of an effective immune response is the high mutation rate of HIV. 
The emergence of viral variants is a great challenge for the immune response. Also 
the highly variable HLA molecules, presenting antigen to antigen-specific T cells 
within the human population makes it even more difficult. In papers II and III we 
combined bioinformatic tools with immunological assays to cope with this high 
variability of the virus and the host and studied the HLA-peptide-TCR recognition 
in more detail.  
 
If the goal of a protective vaccine is not reachable, another achievement would be 
to find a vaccine that would work therapeutically and lower the viral load in HIV 
positive individuals. A lower viral load would slow down disease progression and 
also limit the spread by reducing the risk for transmission. There are some HIV 
positive individuals who are infected but seem to be coping with the virus. They 
are called long-term nonprogressors or elite controllers. Even within progressors 
there are huge differences in disease progression in terms of viral load and CD4+ 
T cell decline. In paper IV we are identifying some immunological and virological 
factors that seem to affect disease outcome.  
Although each study included in this thesis has contributed with important 
information to the field, each answer has raised several new questions. Even 
though this is where this thesis ends, it is only the beginning of finding all the 
answers to really understand the complexity of functional HIV specific T cell 
responses and global virus-host genetic variation.  
 
6.2 Materials and Methods 
6.2.1 Study Cohorts 
Paper I 
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We were fortune enough to get access to PBMC samples from 25 discordant 
couples attending the Gay Men´s Health Clinic in Stockholm, Sweden, in order to 
study the immune responses in EUIs. We received PBMC´s from the HIV negative 
partner, i.e. the EUI, and clinical data of the HIV positive partner. The EUIs had 
answered a questionnaire regarding their sexual behavior, and been examined by 
clinicians every sixth months for detection of HIV and other STI´s. Cells had been 
collected at each examination time point during 2.5 years. None of the 25 
volunteers were detected with HIV or other STI during the study period. Ethical 
approval for this study was given by the ethical committee at Karolinska Institutet, 
and all participants gave their informed consent.  
Papers II and III 
For paper II and III we wanted to study immune responses toward a predicted set 
of HLA class I restricted HIV epitope variants targeted by individuals of various 
ethnical backgrounds infected by diverse HIV subtypes. We selected 31 HIV-1 
infected patients attending the HIV clinic at the Karolinska University Hospital. 
The only inclusion criterion was a detectable viral load (>50 copies/ml) to ensure 
detectable T cell responses. This study cohort was idealistic for our study purpose. 
They differed in route and state of infection, age, gender, treatment history and 
ethnicity as they originated from 13 countries and were infected with different 
HIV subtypes. This study was approved by the Regional Ethical Council in 
Stockholm, Sweden, and all volunteers provided written informed consent.    
Paper IV 
Through our collaboration with Prof Hecht we got the privilege to work with 
exclusive patient material from the OPTIONS cohort at the University of California, 
San Francisco (UCSF) in USA. We were able to examine early T cell responses and 
monitor them over time. Longitudinally drawn PBMC and plasma samples were 
obtained from13 HIV-1 subtype B infected men followed for at least three years 
without any treatment. We had access to all clinical data (CD4 and viral load) 
during the study period as well as information regarding previously identified 
early T cell responses against the HIV-Gag region. The study was approved by an 
ethical committee and all patients provided written informed consent. 
 
6.2.2 ELISPOT versus Flow Cytometry 
Two different immunological assays were used for the studies in this thesis to 
identify HIV specific T cell responses – the ELISPOT IFNγ assay and the ICS flow 
cytometry assay. The ELISPOT IFNγ assay is a fairly easy, cheap and straight 
forward method that detects IFNγ producing cells upon stimulation with an 
antigen (e.g. peptide). The ICS flow cytometry assay is more complicated and 
demands more exclusive and expensive equipment. However, it also provides 
highly sophisticated data and gives the opportunity to distinguish between 
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different cells at a single cell level and to simultaneously identify production of 
several cytokines and chemokines. One drawback with the flow based assay is the 
number of cells needed as the ICS flow cytometry assays require at least 500 000 
cells per test, compared to ELISPOT that only require 150 000-200 000 cells per 
test. Also, the ELISPOT assay is more sensitive and is able to pick up weaker 
responses than the flow cytometry assay. Thus, when working with very limited 
numbers of cells, weak responses, or screening of responses, the ELISPOT assay is 
preferred. Whereas the ICS flow cytometry assay has the great advantage to 
simultaneously identify several phenotypic and functional markers needed to 
understand the characteristics of an immune response and to compare these to 
other responses in intra- and inter-patients studies. In this thesis, assay selection 
was dependent on the aim of each study. The benefits and drawback of these 
assays are further discussed in [118,134]. Additional details can be found in the 
papers I-IV included in this thesis.  
 
6.3 Paper I 
Induction of systemic HIV-1-specific cellular immune responses by oral 
exposure in the uninfected partner of discordant couples 
HIV is a chronic infection and so far we do not seem to be able to clear the 
infection. However, there are some individuals that are less susceptible to HIV 
infection. This fascinating group of people has been exposed to HIV through 
different routes i.e. intravenously, sexually, and horizontally. They have been 
given many names throughout the years, such as highly exposed persistently 
seronegative (HEPS), exposed seronegative (ESN), and exposed uninfected (EU) 
individuals. In this thesis they are referred to as exposed uninfected individuals 
(EUI). The phenomenon of frequent exposure without establishment of infection 
has been well studied in the hope of finding the secret of their reduced 
susceptibility. However, no study of T cell responses on EUIs with exposure only 
via oral sex had been previously performed. Through our collaboration with 
Professor Broliden and Dr Hasselrot, we got the opportunity to study T cell 
responses in a unique cohort consisting of 25 discordant couples who in detailed 
interviews with their physician reported that they practiced protected anal 
intercourse but had unprotected oral sex with their HIV infected spouse.  
We received PBMC´s collected longitudinally during two and a half years time 
from the 25 HIV-uninfected partners of the discordant couples. We also had access 
to all clinical data (CD4 count and viral load) from the HIV infected partner. The 
IFNγ ELISPOT assay was used to identify HIV specific T cell responses using stored 
PBMC samples. We detected T cell responses against HIV in three of the 25 tested 
EUI´s. The frequency of individuals with detected HIV-specific T cell responses in 
other EUI cohorts have differed depending on the study population, rate and route 
of potential exposure as well as assay use. The number of identified responders in 
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our study is comparable to the study by Suy et. al, where two out of the 20 tested 
EUIs in heterosexual discordant couples had an HIV specific T cell response [67]. 
  
One of the responders in our study had a strong HIV-Gag response. This individual 
was highly interesting since his partner had a treatment interruption due to side 
effects during the study period. During this time his viral load went from an 
undetectable level to 286 000 copies/ml. The treatment scheme was changed and 
his viral loads decreased back to undetectable levels. We had the unique 
opportunity to monitor the HIV-specific T cell responses in the HIV negative 
partner before, during, and after the treatment interruption and to study how the 
detected responses correlated to the changing antigen exposure (figure 6a). 
Intracellular cytokine staining and flow cytometry analysis were used to 
distinguish between CD4+ and CD8+ T cells and to identify multiple cytokine, i.e.  
 
 
 
 
   Figure 6 
Viral exposure and multiple cytokine production by HIV-Gag specific CD4+ and CD8+ T 
cells. PBMCs collected at two different time points (marked with black arrows). Viral load 
and treatment history in the partner reveal HIV-exposure (a). PBMCs were stimulated 
with the HIV-Gag p55 peptide pool and activation was measured using the ICS-assay. HIV-
specific T-cell responses were detected in CD4+ T cells (b) and CD8+ T cells (c) at the first 
time point (T0). One year later (T12) the responses were still detectable in the CD4+ T 
cells (d), but not in the CD8+ T cell population (e). ART, antiretroviral therapy. (Figure 
modified from [74])   
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IFNγ, TNFα, MIP-1β and IL2, production. Interestingly, this individual had strong 
CD4+ and CD8+ HIV-specific T cell responses, and produced several cytokines 
upon HIV Gag antigen stimulation (figure 6b-e). The detection of HIV-specific 
CD4+ T cells was not too surprising, as the cells generally recognize antigens that 
have been phagocytosed and presented by HLA class II molecules on professional 
APC. Thus, it is likely that the CD4+ T cell responses were induced by incoming cell 
debris or free viral particles from the exposure that did not establish an infection. 
However, the strong CD8+ T cell response is not as easily explained as it 
recognizes endogenous antigens presented by HLA class I molecules. These 
antigens are generally intracellular antigens, such as viruses or self-antigens in 
cancer cells. Hence, a CD8+ T cell response normally indicates replication of the 
pathogen and would be expected after an HIV infection. However, an alternative 
explanation is that the CD8+ T cells were activated through cross-presentation by 
the HLA class II molecules on professional APCs, i.e. the antigen is presented via 
the extracellular route to the CD8+ T cell on a MHC class II molecule instead 
through the classical MHC class I pathway. We also show that the HIV-specific 
CD4+ T cell response was sustained for at least one year. Even though 
transmission through breast feeding occurs via the oral route, oral sex is not 
considered to be a high risk factor since the task of the normal oral flora is to 
neutralize and block invading pathogens [135]. In this study we show that local 
HIV exposure via oral sex is enough to mount a systemic CD4+ and CD8+ T cell 
response. To answer the question of whether these responses have any protective 
features or if they are merely a trace left by antigen exposure, this topic needs to 
be further investigated. 
 
6.4 Paper II 
Broadly immunogenic HLA class I subtype-restricted elite CTL epitopes 
recognized in a diverse population infected with different HIV-1 subtypes 
The diversity within HIV as well as the genetic variations of the human immune 
system (i.e. HLA and TCR diversity) make it difficult to develop an HIV vaccine as 
well as to study the immune responses against HIV, but needs to be considered 
and evaluated in detail. Validation of vaccine candidates and studies on antigen 
specific T cells might be hampered by the choice of antigens used in the 
immunological assays. Peptide pools corresponding to consensus sequences are 
commonly used, but they might underestimate or even fail to evoke a specific 
response. In this study we aimed at identifying broadly immunogenic epitopes 
that are recognized in an ethnically variable population infected with different 
HIV subtypes. To select epitopes we collaborated with Prof Ole Lund and his 
group at the Technical University of Denmark. They are developing and working 
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Figure 7 
Broad CTL responses detected against HLA supertype restricted epitopes. We found HIV specific 
T cell responses toward a median of six epitopes per patient (a). Responses were detected 
against the majority of the predicted Gag, Pol, Nef, and Env epitopes. The Nef epitopes showed to 
be most immunogenic (b). (Figure modified from [133]) 
 
 
 
with advanced bioinformatic tools including a prediction tool for HLA-class I 
restricted CD8+ T cell epitopes, called NetMHC[136]. Using the bioinformatic tools 
we could work with large datasets and handle the immense genetic diversity of 
the virus and the host. For us, the main benefit was to select epitopes likely to be 
recognized by a large numbers of subjects independent of which HIV type they 
were infected with, and to work with a limited number of optimal 9 amino acid 
long HLA class I restricted epitopes. During the time for the set-up of this study, 
the concept of HLA supertypes was commonly used to simplify the enormous 
amount of HLA alleles present within the human population. A large number of 
HLA alleles were divided into twelve supertypes based on the similarity of the 
peptide they are prone to bind [137,138].  
 
The prediction method used in this study, NetMHC 1.0, predicts all possible 
optimal peptides from a given sequence. The prediction is mainly based on the 
likelihood of binding to a certain HLA-supertype, but also takes into account the 
TAP-transport efficiency and the proteasomal cleavage. In this study we used a set 
of 322 different full-length sequences obtained from the HIV Molecular 
Immunology database (www.hiv.lanl.gov), including the main subtypes and 
circulating recombinant forms. From the sequences 5652 unique peptides were 
predicted to bind to the HLA supertypes. To limit the number of peptides another 
novel algorithm called EpiSelect was used to select peptides, that would give the 
highest coverage possible and an equal distribution of epitopes within the 
different HIV subtypes, as well as to be able to bind the major HLA supertypes 
[137,138]. We ended up with a total of 184 predicted peptides covering the main 
proteins encoded by the HIV-genome.  
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In collaboration with Karolinska University Hospital, we received PBMC from HIV 
positive patients who volunteered for this study. Patients enrolled in this cohort 
were infected with different HIV subtypes and originated from Europe, Africa, Asia 
North America and South America. This gave us access to the desired genetically 
variable study population, which was particularly suitable for the aim of this 
study. The immunogenicity of the 184 predicted peptides were tested by an IFNγ 
ELISPOT assay using PBMC samples obtained from the 31 study subjects. 
Impressively, as the majority of the predicted peptides were immunogenic. We 
found that 114 out of the 184 tested peptides were recognized in by least one of 
the study subjects, and 45 of these were novel epitopes that had not been 
described previously. A median of six epitopes were recognized by each patient 
(figure 7a). The data show that the HIV-Nef epitopes were the most immunogenic; 
96% of tested epitopes were recognized by at least one patient (figure 7b). Also, 
more than 50% of the tested peptides in the HIV-Gag, -Pol and -Env regions were 
recognized, which also indicates a very high immunogenicity. In addition, we 
found 21 epitopes that were highly immunogenic and recognized by four or more 
patients infected with different HIV subtypes. Thus, by using a highly limited 
number of epitopes it is possible to study immunological factors of importance for 
clinical outcome with a global perspective. Ultimately such knowledge will help to 
design future vaccine antigens. 
This study is a good example of the benefits of translation research to gain a 
deeper knowledge in the field. However, bioinformatic tools will only be useful if 
they are accurate and give true information. In this study we got the opportunity 
to use bioinformatic tools to limit the set of desired epitopes for experimental 
work, but also to validate the novel algorithm by testing the immunogenicity of 
the predicted and selected peptides. We found that 66% of the immunologically 
identified responses could be explained by the patients HLA allele belonging to the 
predicted HLA supertype. By extending our analysis and instead use the HLA allele 
prediction tool there was a huge improvement and we could explain 85% of the 
detected responses. Thus, we found that the use of HLA supertypes may not be 
beneficial as it tend to oversimplify the specificity of the HLA-peptide binding. 
Since this study was conducted the HLA class I and II prediction tools have been 
immensely improved, and it is now even possible to predict binding to unknown 
alleles. Further information on this topic can be found in the review written by 
Lundegaard C et all [139].  
At the time of publication of this paper, Fisher et al used another approach to 
combat the high variability within HIV, by inventing the so called mosaic proteins 
for use as a polyvalen vaccine [130]. This was also conducted by in silico methods 
to get the best coverage in broadness of HIV strains, but also depth, meaning 
inclusion of several epitope variants. Since then, these mosaic proteins have been 
used in vaccine trials on rhesus macaques and showed to induce broad and deep 
HIV-specific T cell responses [131,132]. Interestingly, although we were using 
another model and only predicted epitopes giving an optimized viral and human 
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coverage, the vast majority of our 21 elite epitopes were found in the mosaic 
protein. The mosaic vaccine is currently tested on humans and it will be very 
interesting to see whether this increase in response depth and broadness will 
have any effect on HIV-specific responses and disease outcome.  
 
6.5 Paper III 
Interdisciplinary analysis of HIV-specific CD8+ T cell responses against 
variant epitopes reveals restricted TCR promiscuity 
Recognition of a peptide by the TCR is highly sensitive. A virus changes its 
appearance through mutations, which lead to changes in the secondary structure, 
and result in the development of viral variants. The high mutation rate is one of  
 
 
Figure 8 
Similarity between tested and autologous 
peptides influences recognition (a). Fraction of 
responders among the predicted binders that 
show zero, one, or multiple substitutions 
between tested and autologous peptides (b). 
Reduction of response magnitude relative to the 
wild type (i.e. autologous) epitope for variants 
differing at one or more than one position, 
respectively (c). (Figure modified from [140]) 
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the biggest obstacles in understanding the correlates for an effective immune 
response. Amino acid substitutions can lead to structural changes in the epitope 
which in turn can revoke TCR recognition, allowing the virus to escape the 
immunological pressure. On the other hand, cross-recognition between epitope 
variants can occur when the TCR recognizing a particular HLA-peptide complex 
are more flexible, and tolerate some changes within the epitope. However, the 
extent of this cross-recognition was not well understood at the time for this study, 
and had not been investigated in a quantitative manner in a genetically diverse 
population. In this study we once again used bioinformatic tools to understand 
and explain the patterns of epitope-specific CD8+ T cell responses against variant 
epitopes. The results of this study are based on the T cell responses described in 
paper II. We also sequenced the autologous virus (the gag, pol and nef genes) in all 
study subjects and obtained the high-resolution HLA types for the vast majority of 
the study subjects. By having the knowledge of the patients HLA class I alleles and 
the autologous sequences of the virus we used the bioinformatics tool NetMHCpan 
to investigate how peptides were cross-recognized. We compared tested peptide 
sequences with the autologous viral sequences to find out how potential 
differences influenced the detected immune responses as well as the binding 
capacity to the subjects HLA alleles. As expected, we found that the tested peptide 
sequences were significantly more similar to the autologous sequences in patients 
with detectable immune responses than in subjects without a response against the 
tested peptide (figure 8a). Strikingly, if the peptide differed from the autologous 
sequence with only one single amino acid the chance of inducing a response was 
reduced by 40%. One additional substitution further reduced recognition by 50 % 
(figure 8b). This show how fragile the TCR-peptide-HLA recognition is and how 
one single substitution can revoke the immune response.  
We next wanted to see how well tolerated mutations were at different positions of 
the peptide. Therefore we extended the study by selecting sets of peptide-patient 
pairs where the autologous and the tested immunogenic peptide sequences were 
identical. Immune responses were tested against epitope variants including 
commonly found mutations at different positions. We also included alanine 
substitutions for all positions influencing recognition by the TCR. We found that 
substitutions at the different positions were not equally tolerated. Substitutions in 
the third position (P3) seemed to be most well tolerated. Additionally, we looked 
at how the mutations affected the strength of the response, i.e. SFU/million cells. 
We found that the number of mutations will not only affect whether there is a 
response or not, but also the strength of the response (figure 8c).  
Overall this study shows that an interdisciplinary approach is useful to 
understand complex interactions between a genetically diverse virus and host 
immune system, and help us to quantitatively investigate how sensitive these 
interactions are.  
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6.6 Paper IV 
Immunodominant targeting of conserved epitopes in early HIV infection is 
associated with lower plasma viral load and slower CD4+ T cell depletion 
The Swedish cohort at Karolinska University Hospital had the advantage of 
containing HIV infected patients from all over the world which gave us the 
opportunity to study a cohort with subjects that represented the global diversity 
in both ethnicities as well as in virus subtypes and strains. However, although the 
clinicians are making an excellent job in collecting clinical data on these patients, it 
is not possible to know how long they have been infected. Neither did we have 
access to longitudinal samples from the study subjects. Through an established 
collaboration with Prof Douglas Nixon and Prof Rick Hecht at the University of 
California in San Francisco (UCSF), we had access to plasma and PBMC samples 
from HIV infected individuals included in the OPTIONS cohort. This cohort 
consists of more than 600 patients that have been monitored longitudinally from  
 
 
Figure 9 
The mean percentage of IFN-  
producing CD8+ T cells in subjects 
targeting a conserved (square) or a 
variable epitope (triangle) is given at 
four time points (T1 to T4). The IFN-  
production against conserved epitopes 
was sustained over time, while it 
decreased significantly in patients 
targeting a variable epitope (a). 
Targeting of a conserved epitope in 
early infection is associated with lower 
plasma viral load (b) and slower CD4+ 
T cell depletion (c) over time. (Figure 
modified from paper IV) 
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acute or early infection. This gave us the opportunity to study the interaction 
between the immune system and the virus and see how they affected each other 
over time. We also wanted to see how the character (conserved or variable) of the 
targeted antigen affected clinical outcome and disease progression. We selected 
study subjects based on previous identified responses against the HIV-Gag region 
from our study subjects in early infection [141]. We also extended the number of 
tested epitopes by including highly immunogenic HLA-matched peptides from our 
previous study (paper II) [133]. All tested peptides were thus located in the Gag 
region and were HLA matched for each patient. Inclusion criteria for the study 
subjects (n=13) were that they had been longitudinally monitored for at least 
three years without any antiretroviral treatment and that we had access to cell 
and plasma samples from three to four time points, drawn approximately at one 
year intervals. The ICS flow cytometry assay was used to detect HIV specific CD8+ 
T cell responses producing IFNγ, TNFα, MIP-1β and IL2.  
We showed that patients targeting a conserved peptide did maintain the 
magnitude of their epitope-specific CD8+ T cell responses throughout the entire 
study period, while patients targeting a variable peptide had a decrease in the 
magnitude of the responses over time (figure 9a). Despite the loss of magnitude 
against variable epitopes we could not detect any differences in the quality of the 
responses, i.e. the frequency of antigen-specific T cells that produce more than one 
cytokine. Previous studies has shown a significantly higher frequency of such 
polyfunctional antigen specific T cells in HIV infected individuals who have a 
slower disease progression such as LTNP, elite controllers, and HIV-2 infected 
individuals, compared to patients with a faster disease progression and a higher 
viral load. In our study, all patients are progressors, which might explain why we  
did not detect any differences in the frequency of polyfunctional T cells. However, 
another explanation might be that the loss of polyfunctionality occurs at a later 
time-point during chronic infection due to exhaustion of the immune system by 
constant antigen exposure. Most interestingly, the character of the 
immunodominant peptide targeted in primary infection did influence the level of 
viral load (figure 9b) and CD4+ T cell depletion (figure 9c). Hence, patients 
targeting a conserved peptide did have a significantly lower viral load and slower 
CD4+ T cell depletion over time. Despite that they were all progressors, there 
were still significant differences due to the targeted peptide character. The 
existence of a reverse correlation between CD4+ T cell decline and viral load is 
well known, and is an important predictor for disease outcome [46,47]. This study 
shows a clear beneficial role for targeting a conserved peptide in early infection. 
This is likely dependent on the low mutation rate in the epitope region making it 
more difficult for the virus to evade recognition by the development of escape 
mutations. Conserved regions are crucial for viral replication, and mutations in 
these regions have frequently been found to reduce viral fitness.  
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Sequencing of the autologous virus from plasma samples drawn over time is 
ongoing, and will reveal important insight in viral escape mutations and T cell 
cross recognition.  
In conclusion, in the current study we show the importance of targeting the 
appropriate antigen in early infection. Targeting of conserved peptides will not 
only give the subject a more sustained immune response, but it will also affect the 
CD4+ T cell loss and the viral load, hence give an improved disease outcome. Thus, 
it is of importance to consider what antigen to include in future vaccine design. 
Although pre-exciting HIV specific T cell response toward conserved epitopes 
might not protect from infection, it could enable a more sustained control of the 
virus and lead to a slower disease progression in the vaccinees.  
 
 
6.7 Summary of Important Findings 
 
 We show that exposure of HIV via oral sex is enough to mount systemic 
HIV specific CD4+ and CD8+ T cell responses in the exposed uninfected 
partner of discordant couples 
 We identified several highly immunogenic HLA class I restricted epitopes 
that are recognized by CD8+ T cells in a ethnically diverse population 
infected with different HIV subtypes 
 We show that one single mutation in a HLA class I restricted epitope 
recognized by a CD8+ T cell reduces the chance for recognition with 40% 
 We found that the character of the epitope targeted early in HIV infection 
affects the T cell responses and the disease progression over time. The 
CD8+ T cell responses against conserved epitope were sustained over 
time. Most importantly, subjects targeting a conserved epitope had lower 
viral load and a slower CD4+ T cell decline 
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7. Concluding remarks 
Today we have very effective antiviral drugs against HIV that keep the viral load 
under detectable levels and stop disease progression. However, these drugs are 
not a cure. They demand a lifelong treatment involving psychological and 
physical issues, such as side effects. There is also a financial aspect, with high 
costs and distribution difficulties of the drugs in developing countries. 
Therefore, despite the success in the drug development, we still urge for an HIV 
vaccine. An optimal HIV vaccine would work prophylactically and prevent HIV 
infection. This seems to be very hard to achieve. The development of a 
therapeutic vaccine might be a more realistic goal. Such vaccine would control 
the virus and keep the viral load low and prevent immunological exhaustion. A 
high viral load equals a higher risk for transmission, why lowering the viremia 
limits the spread of HIV. For maximum efficacy of a vaccine, it probably should 
induce both the innate and adaptive immune systems, and stimulate T cell and 
neutralizing antibody responses [142]. Some cytokines and chemokines 
produced by cells from both the innate and the adaptive immune system, like 
MIP1α, MIP1β, and RANTES have a direct effect on the ability of the virus to 
infect target cells as they bind to the main co-receptor used by HIV and interfere 
with viral docking and fusion with the host cell [143]. However, the main issue is 
finding the proper antigen for immunization. As we showed in paper IV, the 
immunological targeting of a conserved peptide in early infection is beneficial 
and leads to a lower viral load and a slower CD4+ T cell depletion in HIV infected 
progressors. The identification of antigens that reduce viral fitness is crucial for 
a better disease progression, but finding the weakness of the virus is not enough. 
We also need to consider the ability of presenting such antigen in the infected 
individual, since the high variability of HLA alleles makes antigen presentation 
vary in different individuals. In paper II we proposed a way of handling the 
enormous variability within both the virus as well as the HLA alleles within the 
human population. The approach that we used to identify broadly immunogenic 
conserved epitopes could be useful not only for HIV vaccine design, but also for 
validation of vaccine trials. 
Some studies have shown an adaptation of HIV on a population level. In 
populations with a higher frequency of certain HLA alleles, the circulating virus 
in that area contains HLA escape mutations corresponding to those alleles i.e. 
genetic footprint. This indicates that the pressure from CTLs is driving the HIV 
evolution [95,144,145]. Other studies suggest that the observed epitope clusters 
seen locally are a result of having a common ancestor during rapid transmission 
within a population, and not an adaptation of the virus [146,147]. These two 
theories are not necessarily contradictive. There is no doubt that viral evolution 
within an individual is driven by the cellular immune response in early and 
chronic infection.  
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There are several viral features that make HIV successful and hard to combat. 1) 
HIV has an extremely high mutation rate, which allows escape mutations upon 
pressure from the immune responses and antiretroviral drugs; 2) HIV targets 
and infects immune cells that become hampered, reducing the efficacy of the 
immune response; 3) the recruitment and accumulation of target cells upon 
infection and activation of the cell facilitate the spread to other target cells; 4) 
the viral genome is integrated within the host-cell DNA, establishing latency and 
enabling the virus to hide in infected cells for years; and 5) there is a long 
asymptomatic period after HIV infection. A person can therefore live with HIV 
for years without knowing, and transmit it to several individuals during this 
time.   
Even though the complexity of the virus can seem overwhelming and the 
development of an effective HIV vaccine still lies in the far future, we must 
remain hopeful. Who knows what tomorrow brings? The constant development 
of techniques and assays improves our research and things we are not able to do 
today might be possible in the near future. Also, there may still be unsolved 
enigmas concerning factors associated with protections in the population, such 
as EUI and HIV controllers. New insights might bring knowledge that will help us 
to win this battle. Until then, the single most effective way to stop the spread via 
sexual transmission, the main route of infection, is the use of condoms. The 
increase of HIV and other sexually transmitted infections (STI), especially in the 
younger population, shows that the consequences of sexual behavior still need to 
be addressed. Information and easy access to condoms are extremely important 
and could reduce the spread of HIV. Further effective actions to reduce HIV 
transmission include needle exchange programs for intra venous drug users as 
easy access to clean needles reduces transmission in this risk group 
(http://whqlibdoc.who.int). We also need to change the attitude towards HIV 
and work to limit the stigmatization caused by the disease, which is a severe 
problem that millions of people living with HIV have to face every single day.  
 
   33 
9. Acknowledgment 
To my supervisor Annika Karlsson; Thank you for your guidance and for always 
giving me the space, freedom and confidence to try everything myself, even when 
you knew that you would have to redo it. You have always forced and allowed me 
to grow. And thank you for letting me spend a significant part of my time as a PhD 
student abroad. You made me find my second home – San Francisco.  
To my co-supervisor Douglas Nixon; Thank you for having me visit your lab and 
giving me the opportunity to learn from your excellence, and all the talented 
people at your group. I am so grateful for all the support and for always making 
me feel welcome. I really appreciate all the time we have spent together, both at 
the lab as well as in the wine country and tasteful restaurants. 
To my co-supervisors Jan Albert and Rigmor Thorstensson; Thank you for 
letting me do my PhD under your supervision. SMI has been a very friendly and 
stimulating work place. I feel honored to have respectful names as yours backing 
me up during this journey.      
To all my collaborators all over the world; Rick Hecht – San Francisco, thank you 
for giving me the privilege to work with such exclusive study population as the 
OPTIONS cohort. Thank you for sharing your expertise and for a lot of good times 
together. Ole, Morten, Claus, Ilka and Mette – Copenhagen, thank you for 
excellent collaboration throughout the years! I truly appreciate your knowledge 
and all the fun we have had. Kristina and Klara – Stockholm, it was a true 
pleasure working with you! Thank you for great discussions and lots of fun!  
Huge thanks to all the volunteers at Karolinska University Hospital, Venhälsan 
and OPTIONS cohort. This would not have been possible without you! 
Extra thanks to my “boll-plank” Andreas (Dr Brave) and Malin Stoltz. Thank you 
for always taking the time to listen to me nagging about work and life and for 
showing me how to party for real ;) 
To the entire “former” VHR-group; Thank you Helena for always giving me the 
best hugs, both when I need them and when I just feel like it. Your presence brings 
calm and energy in the same. Thank you Salma for your constant generosity and 
compassion. Thanks to Lina for hours of inspirational talk. I really needed them! 
Thanks to Marcus aka “Pubmed” for helping me with so much! I know I can 
always count on you! Thank you! Thanks to all the students/postdoc; Leda, 
Melissa, Charlotte, Mattias, Dace, Wendy, Johanna, and Viktor. Thank you for 
all the good times throughout the years!!!  You guys are the sweetest! Kajsa and 
Afsaneh, thank you for everything you have helped me with throughout the years! 
My working hours would have been severely more if it wasn´t for you. Marianne, 
Maria and Sarah, it has been a pleasure having you as colleagues! You bring much 
joy and warmth. Thanks to all the rest of the affiliated VHRs. I sure missed you all 
after the “separation”! 
To Sören and all colleagues at SMI and KI; thank you for making the work 
atmosphere so pleasant! “Mördarn”, “Klingan”, David and Emily, you guys rock! 
Extra thanks to everyone at the Immunology department! Special thanks to 
 34 
Karina, Linda, Katarina and Ullis. Thank you Sirkka for being the sweet person 
that you are and for always making my great writing brilliant! Thanks to all my co-
authors for excellent collaboration on my publications. 
All my colleagues in San Fransicso; Thank you for everything during the years! I 
have learned so much from you all and I had the best time ever!!! You have always 
taking such good care of me and made me feel so welcome. A special thanks to Jeff 
Milush and Emily for sharing your knowledge with me and for all the help. I could 
not have done it without you guys! Extra thanks to Lillian, I-Jay, Vanessa, Rex, 
Aashish, Gabe, Jeff Mold, and everybody in the Nixon and the McCune labs.  
I also have people outside of work that I want to thank for everything they have 
given me throughout the years. I know I would not have gone through with this if I 
didn´t have you guys to let loose and freak out with, and just forget about work 
when I´m not working. 
To my sister and best friend Sofia, thank you for bringing so much joy and love 
to my life! You bring me peace, happiness, stability, love, friendship, and 
inspiration everyday! You make me feel grounded and free in the same time and I 
am so grateful that I have you in my life. “Du och jag klarar det ihop, för den ena har 
styrkan och den andra har mod” 
Johan “Rudie”, words cannot express how much you have meant to me during 
these years. You are a true friend and you are always there comforting when I´m 
down and celebrating with me when I´m high on life. I love how we can share the 
beauty in silence, enjoying the archipelago, as well as kill it in the clubs at five am, 
laughing away in the fog.  
To my girls who have been there from the start and closely shared this path with 
me; Emma and Carolina. Here we are. We made it! We have been through so 
much together. We have followed each other during ups and downs, back and 
forth, lefts and rights and wrongs, and slips, and slides. It has been such a luxury to 
have some of my closest friends right next to me at work. The round table at 
“Jönsan” for sure has whiteness some of the most important moments in our lives. 
Thank you for all the fun and all the support during the years! I will never forget 
how you girls rescued me, and I will always be thankful.   
Ullis, you have been there the longest and you know me before I became me, and 
me again. Thank you for always being there and for all the laughters and tears we 
have shared throughout the years!  
Marie, my manic friend, thank you for your never failing support and 
encouragement. Your positive and beautiful mentality is contagious! Thank you 
for “infecting” me with your personality ;) Martin and Malin, my sweet M&M, 
thank you! I will always remember the sound of silence in the beautiful 
archipelago combined with hysterical laughter when I´m thinking of you. Ellen, 
thank you for saving me! For real! My gratitude is beyond words. You are one of 
the most generous and beautiful persons I have ever met. And we have had so 
much fun together! Thank you for encouraging and inspiring with your presence.  
 
   35 
To all my dancing friends all over the world - none mentioned, no one forgotten 
;) You all have a very special place in my heart! When everything went wrong at 
work you gave me a great ending to my bad day. You helped me forget about 
troubles and worries and just filled my life with joy and love. I don´t know where I 
would have been without you guys! Thank you for sharing my passion with me, 
and for encouraging me to break my own boundaries.  
To my girls Lillian and Crykit in California! Your friendship means the world to 
me! No one knows me like you girls do, and I feel like you have become an 
extended part of me. Thank you for everything you are! I love the person I become 
when I´m around you! Thank you for all unforgettable moments of laughter, 
sweating, talking and spontaneous craziness! I am looking forward to all the 
adventures we have ahead of us.  
To the House of Goddess; Aaah!!! I don´t know how this thesis would have been 
written without your life guidance! Thank you for taking me in as your forth 
roommate and bringing out the Goddess within me. I “glove” you girls!!! ;)  
Thank you Agape for helping me stay me. I am setting myself free! And so it is. 
To all my people in the West Coast, USA; Thank you!! You have taking me in, 
giving me roof over my head and showing me the beauty of giving without 
expecting anything back. Thank you for reminding me of what kind of person I 
want to be. Your generosity has touched me in so many ways. Extra thanks to Dan 
and Emily; Thank you!!! I am so grateful for everything you have done for me! I 
loved being your “hustomte” ;) 
Big thanks to all generous contributors of my travel grants throughout the 
years! Sven Gard, SSMF, KI, NIH, Johanna Björkman, Keystone, SIDA, Erik and 
Edit Fernström. You have made my time as a PhD student to the biggest 
adventure of my life. The knowledge and experiences I have gained from all the 
traveling are priceless. It has put me through a lot of social as well as professional 
challenges and forced me to evolve as a scientist as well as a person. Thank you! 
Most of all, thanks to my family! You give me the courage to fly high since I know 
that I always have you there to catch me when I fall. You are my best friends. You 
are my pride, my strength and my inspiration. Thanks to you I am everything I 
want to be and I can do anything I want to do. Your unconditional love is making 
me invincible! Thank you!!! 
And last I want to thank San Francisco! 
You healed my heart when it was broken  
You gave me light in the darkness, and kept me warm when the winter came 
You showed me hope when all I could see was despair 
And you showed love in the least expected places and faces 
My gratitude is beyond any words I know 
So just know that I know 
and that I love you for everything you are 
 
 
 
 
 36 
9. References 
 
1. Gottlieb GJ, Ragaz A, Vogel JV, Friedman-Kien A, Rywlin AM, et al. (1981) A 
preliminary communication on extensively disseminated Kaposi's 
sarcoma in young homosexual men. Am J Dermatopathol 3: 111-114. 
2. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, et al. (1981) 
Pneumocystis carinii pneumonia and mucosal candidiasis in previously 
healthy homosexual men: evidence of a new acquired cellular 
immunodeficiency. N Engl J Med 305: 1425-1431. 
3. Hymes KB, Cheung T, Greene JB, Prose NS, Marcus A, et al. (1981) Kaposi's 
sarcoma in homosexual men-a report of eight cases. Lancet 2: 598-600. 
4. Arya SK, Gallo RC, Hahn BH, Shaw GM, Popovic M, et al. (1984) Homology of 
genome of AIDS-associated virus with genomes of human T-cell leukemia 
viruses. Science 225: 927-930. 
5. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, et al. (1983) 
Isolation of a T-lymphotropic retrovirus from a patient at risk for 
acquired immune deficiency syndrome (AIDS). Science 220: 868-871. 
6. Popovic M, Sarngadharan MG, Read E, Gallo RC (1984) Detection, isolation, 
and continuous production of cytopathic retroviruses (HTLV-III) from 
patients with AIDS and pre-AIDS. Science 224: 497-500. 
7. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, et al. (1986) 
Isolation of a new human retrovirus from West African patients with 
AIDS. Science 233: 343-346. 
8. Kanki PJ, Barin F, M'Boup S, Allan JS, Romet-Lemonne JL, et al. (1986) New 
human T-lymphotropic retrovirus related to simian T-lymphotropic virus 
type III (STLV-IIIAGM). Science 232: 238-243. 
9. Mansson F, Alves A, Silva ZJ, Dias F, Andersson S, et al. (2007) Trends of HIV-1 
and HIV-2 prevalence among pregnant women in Guinea-Bissau, West 
Africa: possible effect of the civil war 1998 1999. Sex Transm Infect 83: 
463-467. 
10. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, et al. (2000) Timing the 
ancestor of the HIV-1 pandemic strains. Science 288: 1789-1796. 
11. Wertheim JO, Worobey M (2009) Dating the age of the SIV lineages that gave 
rise to HIV-1 and HIV-2. PLoS Comput Biol 5: e1000377. 
12. Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K, et al. (2008) 
Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. 
Nature 455: 661-664. 
13. Hahn BH, Shaw GM, De Cock KM, Sharp PM (2000) AIDS as a zoonosis: 
scientific and public health implications. Science 287: 607-614. 
14. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, et al. (1999) Origin of 
HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397: 436-
441. 
15. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, Johnson PR (1989) An 
African primate lentivirus (SIVsm) closely related to HIV-2. Nature 339: 
389-392. 
16. Takebe Y, Uenishi R, Li X (2008) Global molecular epidemiology of HIV: 
understanding the genesis of AIDS pandemic. Adv Pharmacol 56: 1-25. 
17. Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, et al. (2009) A 
new human immunodeficiency virus derived from gorillas. Nat Med 15: 
871-872. 
   37 
18. Vallari A, Holzmayer V, Harris B, Yamaguchi J, Ngansop C, et al. Confirmation 
of Putative HIV-1 Group P in Cameroon. J Virol 85: 1403-1407. 
19. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, et al. (2000) HIV-1 
nomenclature proposal. Science 288: 55-56. 
20. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene 
that inhibits HIV-1 infection and is suppressed by the viral Vif protein. 
Nature 418: 646-650. 
21. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997) 
Quantification of latent tissue reservoirs and total body viral load in HIV-
1 infection. Nature 387: 183-188. 
22. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, et al. (1996) 
Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 
274: 985-989. 
23. Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH (2010) Nature, 
position, and frequency of mutations made in a single cycle of HIV-1 
replication. J Virol 84: 9864-9878. 
24. Drake JW, Charlesworth B, Charlesworth D, Crow JF (1998) Rates of 
spontaneous mutation. Genetics 148: 1667-1686. 
25. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, et al. (2001) 
Evolutionary and immunological implications of contemporary HIV-1 
variation. Br Med Bull 58: 19-42. 
26. Chen J, Powell D, Hu WS (2006) High frequency of genetic recombination is a 
common feature of primate lentivirus replication. J Virol 80: 9651-9658. 
27. Harris RS, Liddament MT (2004) Retroviral restriction by APOBEC proteins. 
Nat Rev Immunol 4: 868-877. 
28. De Smet K, Contreras R (2005) Human antimicrobial peptides: defensins, 
cathelicidins and histatins. Biotechnol Lett 27: 1337-1347. 
29. Izadpanah A, Gallo RL (2005) Antimicrobial peptides. J Am Acad Dermatol 
52: 381-390; quiz 391-382. 
30. Hoof I, Perez CL, Buggert M, Gustafsson RK, Nielsen M, et al. Interdisciplinary 
analysis of HIV-specific CD8+ T cell responses against variant epitopes 
reveals restricted TCR promiscuity. J Immunol 184: 5383-5391. 
31. Leslie A, Price DA, Mkhize P, Bishop K, Rathod A, et al. (2006) Differential 
selection pressure exerted on HIV by CTL targeting identical epitopes but 
restricted by distinct HLA alleles from the same HLA supertype. J 
Immunol 177: 4699-4708. 
32. Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M (2008) Th17 
cytokines and their emerging roles in inflammation and autoimmunity. 
Immunol Rev 226: 87-102. 
33. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. 
Nat Rev Immunol 8: 523-532. 
34. Sallusto F, Lanzavecchia A (2009) Heterogeneity of CD4+ memory T cells: 
functional modules for tailored immunity. Eur J Immunol 39: 2076-2082. 
35. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal 
association of cellular immune responses with the initial control of 
viremia in primary human immunodeficiency virus type 1 syndrome. J 
Virol 68: 4650-4655. 
36. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, et al. (1999) Dramatic rise in 
plasma viremia after CD8(+) T cell depletion in simian immunodeficiency 
virus-infected macaques. J Exp Med 189: 991-998. 
 38 
37. Matano T, Shibata R, Siemon C, Connors M, Lane HC, et al. (1998) 
Administration of an anti-CD8 monoclonal antibody interferes with the 
clearance of chimeric simian/human immunodeficiency virus during 
primary infections of rhesus macaques. J Virol 72: 164-169. 
38. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, et al. (1999) 
Control of viremia in simian immunodeficiency virus infection by CD8+ 
lymphocytes. Science 283: 857-860. 
39. Sandberg JK, Fast NM, Nixon DF (2001) Functional heterogeneity of 
cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. 
J Immunol 167: 181-187. 
40. Voskoboinik I, Smyth MJ, Trapani JA (2006) Perforin-mediated target-cell 
death and immune homeostasis. Nat Rev Immunol 6: 940-952. 
41. Trapani JA, Smyth MJ (2002) Functional significance of the 
perforin/granzyme cell death pathway. Nat Rev Immunol 2: 735-747. 
42. Melief CJ (2003) Mini-review: Regulation of cytotoxic T lymphocyte 
responses by dendritic cells: peaceful coexistence of cross-priming and 
direct priming? Eur J Immunol 33: 2645-2654. 
43. Kroger CJ, Flores RR, Morillon M, Wang B, Tisch R (2010) Dysregulation of 
thymic clonal deletion and the escape of autoreactive T cells. Arch 
Immunol Ther Exp 58: 449-457. 
44. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, et al. (1996) 
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. 
Science 272: 1167-1170. 
45. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, et al. (2002) HIV 
preferentially infects HIV-specific CD4+ T cells. Nature 417: 95-98. 
46. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, et al. (2003) Severe 
CD4+ T-cell depletion in gut lymphoid tissue during primary human 
immunodeficiency virus type 1 infection and substantial delay in 
restoration following highly active antiretroviral therapy. J Virol 77: 
11708-11717. 
47. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L (1998) Biological and 
virologic characteristics of primary HIV infection. Ann Intern Med 128: 
613-620. 
48. Alimonti JB, Ball TB, Fowke KR (2003) Mechanisms of CD4+ T lymphocyte 
cell death in human immunodeficiency virus infection and AIDS. J Gen 
Virol 84: 1649-1661. 
49. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+ T 
cell depletion during all stages of HIV disease occurs predominantly in 
the gastrointestinal tract. J Exp Med 200: 749-759. 
50. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, et al. (2000) Natural 
history of human immunodeficiency virus type 1 viremia after 
seroconversion and proximal to AIDS in a large cohort of homosexual 
men. Multicenter AIDS Cohort Study. J Infect Dis 181: 872-880. 
51. Kahn JO, Walker BD (1998) Acute human immunodeficiency virus type 1 
infection. N Engl J Med 339: 33-39. 
52. Douek DC (2003) Disrupting T-cell homeostasis: how HIV-1 infection causes 
disease. AIDS Rev 5: 172-177. 
53. Ranki A, Mattinen S, Yarchoan R, Broder S, Ghrayeb J, et al. (1989) T-cell 
response towards HIV in infected individuals with and without 
zidovudine therapy, and in HIV-exposed sexual partners. Aids 3: 63-69. 
   39 
54. Hader SL, Hodge TW, Buchacz KA, Bray RA, Padian NS, et al. (2002) 
Discordance at human leukocyte antigen-DRB3 and protection from 
human immunodeficiency virus type 1 transmission. J Infect Dis 185: 
1729-1735. 
55. Lockett SF, Robertson JR, Brettle RP, Yap PL, Middleton D, et al. (2001) 
Mismatched human leukocyte antigen alleles protect against heterosexual 
HIV transmission. J Acquir Immune Defic Syndr 27: 277-280. 
56. Hasselrot K, Saberg P, Hirbod T, Soderlund J, Ehnlund M, et al. (2009) Oral 
HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected 
men who have sex with men. Aids 23: 329-333. 
57. Fowke KR, Nagelkerke NJ, Kimani J, Simonsen JN, Anzala AO, et al. (1996) 
Resistance to HIV-1 infection among persistently seronegative prostitutes 
in Nairobi, Kenya. Lancet 348: 1347-1351. 
58. Legrand FA, Nixon DF, Loo CP, Ono E, Chapman JM, et al. (2006) Strong HIV-
1-specific T cell responses in HIV-1-exposed uninfected infants and 
neonates revealed after regulatory T cell removal. PLoS One 1: e102. 
59. Iqbal SM, Ball TB, Kimani J, Kiama P, Thottingal P, et al. (2005) Elevated T cell 
counts and RANTES expression in the genital mucosa of HIV-1-resistant 
Kenyan commercial sex workers. J Infect Dis 192: 728-738. 
60. Hirbod T, Nilsson J, Andersson S, Uberti-Foppa C, Ferrari D, et al. (2006) 
Upregulation of interferon-alpha and RANTES in the cervix of HIV-1-
seronegative women with high-risk behavior. J Acquir Immune Defic 
Syndr 43: 137-143. 
61. Trabattoni D, Caputo SL, Maffeis G, Vichi F, Biasin M, et al. (2004) Human 
alpha defensin in HIV-exposed but uninfected individuals. J Acquir 
Immune Defic Syndr 35: 455-463. 
62. Zapata W, Rodriguez B, Weber J, Estrada H, Quinones-Mateu ME, et al. (2008) 
Increased levels of human beta-defensins mRNA in sexually HIV-1 
exposed but uninfected individuals. Curr HIV Res 6: 531-538. 
63. Ball TB, Ji H, Kimani J, McLaren P, Marlin C, et al. (2007) Polymorphisms in 
IRF-1 associated with resistance to HIV-1 infection in highly exposed 
uninfected Kenyan sex workers. Aids 21: 1091-1101. 
64. Bernard NF, Yannakis CM, Lee JS, Tsoukas CM (1999) Human 
immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in 
HIV-exposed seronegative persons. J Infect Dis 179: 538-547. 
65. Clerici M, Giorgi JV, Chou CC, Gudeman VK, Zack JA, et al. (1992) Cell-
mediated immune response to human immunodeficiency virus (HIV) type 
1 in seronegative homosexual men with recent sexual exposure to HIV-1. 
J Infect Dis 165: 1012-1019. 
66. Kaul R, Plummer FA, Kimani J, Dong T, Kiama P, et al. (2000) HIV-1-specific 
mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant 
prostitutes in Nairobi. J Immunol 164: 1602-1611. 
67. Suy A, Castro P, Nomdedeu M, Garcia F, Lopez A, et al. (2007) Immunological 
profile of heterosexual highly HIV-exposed uninfected individuals: 
predominant role of CD4 and CD8 T-cell activation. J Infect Dis 196: 1191-
1201. 
68. Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, et al. (2002) Cross-clade HIV-1-
specific neutralizing IgA in mucosal and systemic compartments of HIV-1-
exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr 
30: 413-420. 
 40 
69. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, et al. (2000) Mucosal and 
plasma IgA from HIV-exposed seronegative individuals neutralize a 
primary HIV-1 isolate. Aids 14: 1917-1920. 
70. Bergmeier LA, Lehner T (2006) Innate and adaptive mucosal immunity in 
protection against HIV infection. Adv Dent Res 19: 21-28. 
71. Hirbod T, Kaul R, Reichard C, Kimani J, Ngugi E, et al. (2008) HIV-neutralizing 
immunoglobulin A and HIV-specific proliferation are independently 
associated with reduced HIV acquisition in Kenyan sex workers. Aids 22: 
727-735. 
72. Lacap PA, Huntington JD, Luo M, Nagelkerke NJ, Bielawny T, et al. (2008) 
Associations of human leukocyte antigen DRB with resistance or 
susceptibility to HIV-1 infection in the Pumwani Sex Worker Cohort. Aids 
22: 1029-1038. 
73. Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, et al. (2001) CD8(+) 
lymphocytes respond to different HIV epitopes in seronegative and 
infected subjects. J Clin Invest 107: 1303-1310. 
74. Perez CL, Hasselrot K, Bratt G, Broliden K, Karlsson AC (2010) Induction of 
systemic HIV-1-specific cellular immune responses by oral exposure in 
the uninfected partner of discordant couples. Aids 24: 969-974. 
75. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, et al. (1996) Resistance 
to HIV-1 infection in caucasian individuals bearing mutant alleles of the 
CCR-5 chemokine receptor gene. Nature 382: 722-725. 
76. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, et al. (1996) 
Genetic restriction of HIV-1 infection and progression to AIDS by a 
deletion allele of the CKR5 structural gene. Hemophilia Growth and 
Development Study, Multicenter AIDS Cohort Study, Multicenter 
Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. 
Science 273: 1856-1862. 
77. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, et al. (1997) The role 
of viral phenotype and CCR-5 gene defects in HIV-1 transmission and 
disease progression. Nat Med 3: 338-340. 
78. Lucotte G, Dieterlen F (2003) More about the Viking hypothesis of origin of 
the delta32 mutation in the CCR5 gene conferring resistance to HIV-1 
infection. Infect Genet Evol 3: 293-295. 
79. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, et al. (2007) Male 
circumcision for HIV prevention in young men in Kisumu, Kenya: a 
randomised controlled trial. Lancet 369: 643-656. 
80. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, et al. (2007) Male 
circumcision for HIV prevention in men in Rakai, Uganda: a randomised 
trial. Lancet 369: 657-666. 
81. Deeks SG, Walker BD (2007) Human immunodeficiency virus controllers: 
mechanisms of durable virus control in the absence of antiretroviral 
therapy. Immunity 27: 406-416. 
82. Migueles SA, Tilton JC, Connors M (2004) Advances in understanding 
immunologic control of HIV infection. Curr HIV/AIDS Rep 1: 12-17. 
83. Walker BD (2007) Elite control of HIV Infection: implications for vaccines 
and treatment. Top HIV Med 15: 134-136. 
84. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB (1994) Virus-specific 
CD8+ cytotoxic T-lymphocyte activity associated with control of viremia 
in primary human immunodeficiency virus type 1 infection. J Virol 68: 
6103-6110. 
   41 
85. Friedrich TC, Valentine LE, Yant LJ, Rakasz EG, Piaskowski SM, et al. (2007) 
Subdominant CD8+ T-cell responses are involved in durable control of 
AIDS virus replication. J Virol 81: 3465-3476. 
86. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, et al. (1997) Late 
escape from an immunodominant cytotoxic T-lymphocyte response 
associated with progression to AIDS. Nat Med 3: 212-217. 
87. Goulder PJ, Watkins DI (2008) Impact of MHC class I diversity on immune 
control of immunodeficiency virus replication. Nat Rev Immunol 8: 619-
630. 
88. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, et al. (1999) HLA 
and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. 
Science 283: 1748-1752. 
89. Tang J, Costello C, Keet IP, Rivers C, Leblanc S, et al. (1999) HLA class I 
homozygosity accelerates disease progression in human 
immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 15: 
317-324. 
90. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, et al. (2006) HLA Alleles 
Associated with Delayed Progression to AIDS Contribute Strongly to the 
Initial CD8(+) T Cell Response against HIV-1. PLoS Med 3: e403. 
91. Costello C, Tang J, Rivers C, Karita E, Meizen-Derr J, et al. (1999) HLA-B*5703 
independently associated with slower HIV-1 disease progression in 
Rwandan women. Aids 13: 1990-1991. 
92. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al. 
(2000) HLA B*5701 is highly associated with restriction of virus 
replication in a subgroup of HIV-infected long term nonprogressors. Proc 
Natl Acad Sci U S A 97: 2709-2714. 
93. An P, Winkler CA (2010) Host genes associated with HIV/AIDS: advances in 
gene discovery. Trends Genet 26: 119-131. 
94. Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, et al. (2009) Variable 
fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) 
response. PLoS Pathog 5: e1000365. 
95. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004) 
Dominant influence of HLA-B in mediating the potential co-evolution of 
HIV and HLA. Nature 432: 769-775. 
96. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, et al. (2001) Effect of a 
single amino acid change in MHC class I molecules on the rate of 
progression to AIDS. N Engl J Med 344: 1668-1675. 
97. Steinle A, Falk K, Rotzschke O, Gnau V, Stevanovic S, et al. (1996) Motif of 
HLA-B*3503 peptide ligands. Immunogenetics 43: 105-107. 
98. Kosmrlj A, Read EL, Qi Y, Allen TM, Altfeld M, et al. (2010) Effects of thymic 
selection of the T-cell repertoire on HLA class I-associated control of HIV 
infection. Nature 465: 350-354. 
99. Borghans JA, Molgaard A, de Boer RJ, Kesmir C (2007) HLA alleles associated 
with slow progression to AIDS truly prefer to present HIV-1 p24. PLoS 
One 2: e920. 
100. Carrington M, O'Brien SJ (2003) The influence of HLA genotype on AIDS. 
Annu Rev Med 54: 535-551. 
101. Hoof I, Kesmir C, Lund O, Nielsen M (2008) Humans with chimpanzee-like 
major histocompatibility complex-specificities control HIV-1 infection. 
Aids 22: 1299-1303. 
 42 
102. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. 
(2007) CD8+ T-cell responses to different HIV proteins have discordant 
associations with viral load. Nat Med 13: 46-53. 
103. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior 
control of HIV-1 replication by CD8+ T cells is reflected by their avidity, 
polyfunctionality, and clonal turnover. J Exp Med 204: 2473-2485. 
104. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV 
nonprogressors preferentially maintain highly functional HIV-specific 
CD8+ T cells. Blood 107: 4781-4789. 
105. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, et al. (2008) 
Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J 
Immunol 38: 350-363. 
106. Horton H, Frank I, Baydo R, Jalbert E, Penn J, et al. (2006) Preservation of T 
cell proliferation restricted by protective HLA alleles is critical for 
immune control of HIV-1 infection. J Immunol 177: 7406-7415. 
107. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, et al. (2005) HIV-1-
specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent 
proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A 102: 
7239-7244. 
108. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, et al. 
(2002) HIV-specific CD8+ T cell proliferation is coupled to perforin 
expression and is maintained in nonprogressors. Nat Immunol 3: 1061-
1068. 
109. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, et al. (2008) Lytic 
granule loading of CD8+ T cells is required for HIV-infected cell 
elimination associated with immune control. Immunity 29: 1009-1021. 
110. Sherman GG, Scott LE, Galpin JS, Kuhn L, Tiemessen CT, et al. (2002) CD38 
expression on CD8(+) T cells as a prognostic marker in vertically HIV-
infected pediatric patients. Pediatr Res 51: 740-745. 
111. Vigano A, Saresella M, Villa ML, Ferrante P, Clerici M (2000) CD38+CD8+ T 
cells as a marker of poor response to therapy in HIV-infected individuals. 
Chem Immunol 75: 207-217. 
112. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1 
expression on HIV-specific T cells is associated with T-cell exhaustion and 
disease progression. Nature 443: 350-354. 
113. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, et al. (2006) 
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to 
reversible immune dysfunction. Nat Med 12: 1198-1202. 
114. Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, et al. (2009) Antigen 
sensitivity is a major determinant of CD8+ T-cell polyfunctionality and 
HIV-suppressive activity. Blood 113: 6351-6360. 
115. Harari A, Cellerai C, Enders FB, Kostler J, Codarri L, et al. (2007) Skewed 
association of polyfunctional antigen-specific CD8 T cell populations with 
HLA-B genotype. Proc Natl Acad Sci U S A 104: 16233-16238. 
116. Harari A, Petitpierre S, Vallelian F, Pantaleo G (2004) Skewed 
representation of functionally distinct populations of virus-specific CD4 T 
cells in HIV-1-infected subjects with progressive disease: changes after 
antiretroviral therapy. Blood 103: 966-972. 
117. Rehr M, Cahenzli J, Haas A, Price DA, Gostick E, et al. (2008) Emergence of 
polyfunctional CD8+ T cells after prolonged suppression of human 
   43 
immunodeficiency virus replication by antiretroviral therapy. J Virol 82: 
3391-3404. 
118. Makedonas G, Betts MR (2011) Living in a house of cards: re-evaluating 
CD8+ T-cell immune correlates against HIV. Immunol Rev 239: 109-124. 
119. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, et al. (1995) Primary isolates 
of human immunodeficiency virus type 1 are relatively resistant to 
neutralization by monoclonal antibodies to gp120, and their 
neutralization is not predicted by studies with monomeric gp120. J Virol 
69: 101-109. 
120. Ross AL, Brave A, Scarlatti G, Manrique A, Buonaguro L (2010) Progress 
towards development of an HIV vaccine: report of the AIDS Vaccine 2009 
Conference. Lancet Infect Dis 10: 305-316. 
121. Lu S (2009) Heterologous prime-boost vaccination. Curr Opin Immunol 21: 
346-351. 
122. Ezzell C (1987) Trials of vaccine against AIDS to begin in humans. Nature 
328: 747. 
123. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, et al. (1996) 
Immunization with envelope subunit vaccine products elicits neutralizing 
antibodies against laboratory-adapted but not primary isolates of human 
immunodeficiency virus type 1. The National Institute of Allergy and 
Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 173: 340-
348. 
124. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, et al. (2005) 
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 
vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665. 
125. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) 
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent 
recombinant glycoprotein 120 HIV-1 vaccine among injection drug users 
in Bangkok, Thailand. J Infect Dis 194: 1661-1671. 
126. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) 
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step 
Study): a double-blind, randomised, placebo-controlled, test-of-concept 
trial. Lancet 372: 1881-1893. 
127. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. 
(2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection 
in Thailand. N Engl J Med 361: 2209-2220. 
128. Barouch DH (2008) Challenges in the development of an HIV-1 vaccine. 
Nature 455: 613-619. 
129. Korber BT, Letvin NL, Haynes BF (2009) T-cell vaccine strategies for human 
immunodeficiency virus, the virus with a thousand faces. J Virol 83: 8300-
8314. 
130. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, et al. (2007) 
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in 
global HIV-1 variants. Nat Med 13: 100-106. 
131. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, et al. (2010) 
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune 
responses in rhesus monkeys. Nat Med 16: 319-323. 
132. Santra S, Liao HX, Zhang R, Muldoon M, Watson S, et al. (2010) Mosaic 
vaccines elicit CD8+ T lymphocyte responses that confer enhanced 
immune coverage of diverse HIV strains in monkeys. Nat Med 16: 324-
328. 
 44 
133. Perez CL, Larsen MV, Gustafsson R, Norstrom MM, Atlas A, et al. (2008) 
Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes 
recognized in a diverse population infected with different HIV-1 subtypes. 
J Immunol 180: 5092-5100. 
134. Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, et al. (2003) 
Comparison of the ELISPOT and cytokine flow cytometry assays for the 
enumeration of antigen-specific T cells. J Immunol Methods 283: 141-153. 
135. Fultz PN (1986) Components of saliva inactivate human immunodeficiency 
virus. Lancet 2: 1215. 
136. Larsen MV, Lundegaard C, Lamberth K, Buus S, Brunak S, et al. (2005) An 
integrative approach to CTL epitope prediction: a combined algorithm 
integrating MHC class I binding, TAP transport efficiency, and 
proteasomal cleavage predictions. Eur J Immunol 35: 2295-2303. 
137. Lund O, Nielsen M, Kesmir C, Petersen AG, Lundegaard C, et al. (2004) 
Definition of supertypes for HLA molecules using clustering of specificity 
matrices. Immunogenetics 55: 797-810. 
138. Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the 
vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50: 
201-212. 
139. Lundegaard C, Lund O, Buus S, Nielsen M (2010) Major histocompatibility 
complex class I binding predictions as a tool in epitope discovery. 
Immunology 130: 309-318. 
140. Hoof I, Perez CL, Buggert M, Gustafsson RK, Nielsen M, et al. (2010) 
Interdisciplinary analysis of HIV-specific CD8+ T cell responses against 
variant epitopes reveals restricted TCR promiscuity. J Immunol 184: 
5383-5391. 
141. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, et al. (2009) Human 
immunodeficiency virus type 1-specific CD8+ T-cell responses during 
primary infection are major determinants of the viral set point and loss of 
CD4+ T cells. J Virol 83: 7641-7648. 
142. Lahiri A, Das P, Chakravortty D (2008) Engagement of TLR signaling as 
adjuvant: towards smarter vaccine and beyond. Vaccine 26: 6777-6783. 
143. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, et al. (1995) 
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-
suppressive factors produced by CD8+ T cells. Science 270: 1811-1815. 
144. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, et al. (2009) 
Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458: 641-
645. 
145. Yusim K, Kesmir C, Gaschen B, Addo MM, Altfeld M, et al. (2002) Clustering 
patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency 
virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 
global variation. J Virol 76: 8757-8768. 
146. Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, et al. (2007) 
Founder effects in the assessment of HIV polymorphisms and HLA allele 
associations. Science 315: 1583-1586. 
147. Schmid BV, Kesmir C, de Boer RJ (2009) The distribution of CTL epitopes in 
HIV-1 appears to be random, and similar to that of other proteomes. BMC 
Evol Biol 9: 184. 
 
 
 
   45 
 
 
 
10. Related publication - Populärvetenskaplig artikel 
 
I Pérez CL, Karlsson AC. Att identifiera komponenter till ett optimerat 
hivvacin. Perspektiv på HIV, nr 21/2010 
 
 
PERSPEKTIV PÅ HIV NR 21/2010  1317
Trots alla ansträngningar som gjorts se-
dan hiv först upptäcktes finns i dag ingen 
behandling som kan bota sjukdomen el-
ler något vaccin som kan förhindra smitt-
spridning eller sakta ned sjukdomsför-
loppet. Men tack vare all den forskning 
som utförts har vi i dag en mycket bättre 
förståelse för hur viruset och immunför-
svaret fungerar. Informationen om viru-
sets egenskaper har lett till att vi har kom-
mit en bra bit på vägen när det gäller be-
handlingen av hiv, som i dag fungerar 
bra och med vilken vi kan attackera viru-
set från flera olika håll. Men än saknas 
mycket kunskap för att nå fram till ett ef-
fektivt vaccin som kan förhindra smitt-
spriding. Ett stort problem är att vi i dag 
fortfarande inte exakt vet vilka egenska-
per ett immunförsvar ska ha för att vara 
effektivt mot hiv. I vår forskargrupp, ledd 
av docent Annika Karlsson, arbetar vi 
med att identifiera komponenter som le-
der till ett effektivt immunsvar med ett 
tvärvetenskapligt synsätt. Vi binder sam-
man våra immunologiska och virologiska 
kunskaper med bioinformatiska, genom 
att samarbeta med professor Ole Lund 
och hans grupp på Tekniska universitetet 
i Danmark. Genom detta samarbete har 
vi lyckats utvinna mycket information 
om hur viruset påverkas av immunsyste-
met och vice versa. Vi tror att vi med den-
na typ av nya kunskaper kommer att 
kunna bidra till utvecklingen av morgon-
dagens hivvaccinkandidater. 
Hur känner immunförsvaret 
igen en mikroorganism? 
I kroppen finns en armé av immunceller 
som jobbar och kommunicerar med var-
andra och fyller olika funktioner för att 
eliminera invaderande mikroorganismer 
så som virus och bakterier. En del av im-
munförsvaret kallas för ”det medfödda 
immunsystemet”, och är det som sätter 
igång först vid ett angrepp av mikroorga-
nismer. Den här delen av immunförsva-
ret har fördelen att det agerar väldigt 
snabbt och kan ofta eliminera infektio-
nen i ett tidigt skede. Men ibland räcker 
det inte till och då kan det så kallade 
”adaptiva immunsystemet”, som består 
av bland annat T- och B-celler, ta över. 
Det här svaret tar längre tid att utveckla 
eftersom T- och B-cellerna behöver tid att 
mogna och få lärdom om exakt vad det är 
för mikroorganism (till exempel hiv) de 
slåss emot. De upplärda T- och B-cellerna 
blir specifika och känner sedan bara igen 
just den mikroorganism de blivit utbil-
dade för att känna igen. De hivspecifika 
T-cellerna lärs upp genom att få små frag-
ment av hiv presenterade för sig via så 
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kallade HLA-molekyler på cellytan av an-
tigen-presenterande celler (APC). De hiv-
specifika T-cellerna mognar, cirkulerar i 
blod och vävnad där de känner igen hiv-
infekterade celler som visar samma frag-
ment bundet till HLA-molekylerna som 
T-cellerna utbildats för att känna igen (Fi-
gur 1). Det finns väldigt många olika vari-
anter av HLA-molekyler och vilka frag-
ment av hiv som kan presenteras via de 
olika varianterna är väldigt specifikt och 
skiljer sig mycket åt. Det betyder att alla 
individer som får en infektion inte kom-
mer att presentera och känna igen sam-
ma fragment av mikroorganismen eller 
reagera på samma sätt. 
De utbildade specifika T-cellerna går ut 
i strid (de kallas effektorceller) och kan 
fånga in och oskadliggöra mikroorganis-
men direkt eller döda de celler som blivit 
infekterade, samt tillkalla förstärkning. 
Vissa av de utbildade immuncellerna blir 
i stället så kallade minnesceller. Minnes-
celler kan leva länge i kroppen och har 
redan all kunskap om mikroorganismens 
karaktär, vilket gör att nästa gång de kom-
mer i kontakt med denna så kan dessa 
celler snabbt gå ut i strid direkt med full 
kraft utan att behöva utbildas innan. Vis-
sa sjukdomar har vi lättare att bilda min-
nesceller mot och dessa blir vi därför inte 
sjuka av andra gången vi träffar på dem. 
Hur fungerar ett vaccin?
Det är genom att efterlikna ”utbildning-
en” av specifika minnesceller som vaccin 
fungerar. Genom att simulera en mikro-
organism såsom en bakterie (till exempel 
pneumokocker) eller ett virus (till exem-
pel mässling, röda hund, och vattkoppor) 
kan vi sätta igång hela den träning som 
kroppen normalt gör då den träffar på en 
mikroorganism och på så sätt erhålla en 
armé av utbildade minnesceller. Det gör 
att den dag vi stöter på mikroorganismen 
ifråga som vi vaccinerats mot så kommer 
dessa minnesceller att kunna agera 
snabbt och stoppa infektionen vid ett ti-
digt stadium så att vi inte blir sjuka. Ett 
vaccin hjälper således kroppen att själv ta 
hand om infektionen och kan fortfarande 
fungera lång tid efter vaccinationen, till 
skillnad mot mediciner. Mediciner age-
rar efter att man blivit infekterad och 
hjälper kroppen att eliminera mikroorga-
nismen, men har ingen långvarig effekt.
Varför behövs det ett hivvaccin?
I västvärlden har vi i dag mediciner mot 
de flesta sjukdomsalstrande bakterier och 
vissa virus (även om antibiotikaresistenta 
bakterier dessvärre är ett växande pro-
blem). En del av dem verkar mot själva 
symptomen medan andra verkar mot den 
mikroorganism som gjort oss sjuka. När 
det kommer till hiv så finns det i dag inga 
mediciner som kan eliminera infektio-
nen, men de kan attackera viruset från 
flera olika håll vilket stoppar produktio-
nen av nya viruspartiklar och på så sätt 
bromsas sjukdomsförloppet mot aids. 
Dessvärre finns det alltid en liten pool av 
virus som ligger gömda i cellerna och 
som dagens mediciner inte kommer åt. 
Dessa virus kommer snabbt att öka i an-
tal så fort medicineringen upphör. 
Bromsmediciner har förbättrat och för-
längt livet på flera miljoner hivinfekterade 
individer, men det är en livslång behand-
ling som kan medföra biverkningar på 
kort och lång sikt. Det är även viktigt att 
man alltid tar alla sina tabletter på rätt sätt 
eftersom de annars kan tappa sin effekt 
då viruset kan utveckla resistens mot 
medicinerna. Mediciner är även dyra och 
kan vara svåra att distribuera i vissa ut-
vecklingsländer, till exempel i krigsdrab-
bade länder, där det råder brister i sam-
hällsstrukturen. Trots att bromsmedici-
nerna fungerar bra vore det därför fördel-
aktigt att ha ett vaccin. Den idealiska 
lösningen vore om vi lyckades utveckla 
ett förebyggande vaccin, så att den vacci-
nerade inte kunde infekteras med hiv. 
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Men ett behandlande (även kallat tera-
peutiskt) vaccin som hjälpte den som re-
dan smittats med att utbilda ett bättre im-
munsvar så att virusnivåerna hålls nere, 
skulle också innebära stora framsteg. Vid 
låga virusnivåer går utvecklingen mot 
aids långsammare. Den smittade skulle 
då kunna leva längre utan mediciner, vil-
ket skulle minska risken för biverkningar 
och utveckling av resistens. 
Svårt utveckla ett vaccin mot hiv 
då viruset ständigt förändras
Det största problemet med hiv är att viru-
set förändras väldigt snabbt och dess ut-
seende ändras så pass mycket att immun-
systemet har svårt att känna igen det. Vi-
ruset är så variabelt att de varianter som 
kan ses hos en enda infekterad individ är 
fler än hela den världsomspännande va-
riationen av influensavirus under en epi-
demi. Det betyder att trots att cellerna gör 
sitt jobb och utbildar immunsystemet för 
att känna igen viruset, hinner det inte 
med att lära om i samma hastighet som 
viruset förändras, utan ligger hela tiden 
steget efter. 
Tanken med ett hivvaccin är att man i 
stället ska ligga steget före, men än så 
länge har ingen lyckats framställa ett så-
dant vaccin. Mycket forskning har foku-
serat på att utveckla ett hivvaccin och flera 
kandidater har sett lovande ut samt gett 
upphov till hivspecifika immunceller i de 
vaccinerade individerna. Men när den 
vaccinerade senare träffat på viruset på 
riktigt så har inte dessa immunsvar kun-
nat stoppa infektionen. Efter det hitills 
mest lyckade vaccinförsöket, Thai fas III-
försöket (RV144), såg man ett visst låg-
gradigt skydd mot infektion i vaccingrup-
pen, men ingen skillnad i sjukdomsför-
loppet efter att man hade blivit infekte-
rad. Hittills har inga av de andra 
vaccinförsöken heller lyckats med att hål-
la nere virusnivåerna i dem som smittats. 
Ett av de större vaccinförsöken, STEP, av-
bröts i november 2007 då det inte visade 
sig ge något skydd emot hivinfektion 
utan snarare tvärtom. På en stor virus-
konferens (CROI) som hölls i San Fran-
cisco i februari tidigare i år presenterades 
de senaste resultaten från fortsatta stu-
dier på de som blivit smittade trots att de 
vaccinerats. De kunde då se att viruset 
 
Figur I. Hivspecifik T-cell känner igen virusinfekterad cell. Den hivinfekterade cellen visar upp 
ett litet fragment av viruset för T-cellen genom att binda och presentera det på en HLA-molekyl 
på cellens yta. Då T-cellen binder och känner igen fragmentet kan den döda den virusinfekte-
rade cellen samt tilkalla hjälp och oskadliggöra virus.
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såg lite annorlunda ut hos de infekterade 
individer som vaccinerats jämfört med 
de som inte fått vaccin. Detta kan betyda 
att de upplärda immuncellerna antingen 
stoppade infektion av virus som var likt 
just det de blivit utbildade för, men inte 
hade något skydd emot alla andra varian-
ter. Ett mer troligt alternativ är att de upp-
lärda immuncellerna gjorde sitt jobb ef-
ter att individen blivit infekterad, men att 
immunförsvaret inte klarade av att känna 
igen viruset när det förändrade sig. Återi-
gen låg immunsystemet steget efter viru-
set. I båda fallen visar detta ändå att vac-
cinet hade haft någon typ av påverkan på 
hiv, men att viruset inte hade haft några 
större problem att byta utseende och 
gömma sig för de utbildade immuncel-
lerna.
Finns det någon lösning?
Hur skulle man då kunna träna immun-
systemet så att viruset inte kan fly ifrån 
det? Finns det delar av viruset som är vik-
tigare än andra, och där viruset inte kan 
ändras? Ett sätt att ta reda på det är att 
titta på hur alla olika virusvarianter ser ut 
och studera huruvida det finns delar av 
viruset som är väldigt lika mellan dessa 
varianter. Det betyder att viruset inte kan 
förändra sig i dessa regioner, utan måste 
bibehålla ett snarlikt utseende för att inte 
tappa sin funktion och förstöras. Om 
man kunde identifiera fragment som kan 
presenteras från dessa regioner skulle 
immunsystemet kunna ”tränas” upp och 
lära sig att känna igen just dessa, och då 
skulle viruset inte kunna fly undan. 
En annan viktig faktor att ta hänsyn till 
är variationen mellan människors HLA-
molekyler, vilket gör att inte alla kan pre-
sentera och känna igen samma fragment. 
Även om man skulle identifiera fragment 
som är kritiska för viruset, så skulle de 
kanske inte kunna presenteras för im-
munsystemet om man inte hade ”rätt” 
HLA-molekyl. Idealet vore att hitta frag-
ment från ursprungliga delar av viruset 
som kunde kännas igen, samt vara möj-
liga att presenteras i majoriteten av den 
mänskliga befolkningens HLA-moleky-
ler. 
Identifiering av optimerade 
T-cells svar
I dag vet vi ännu inte vilka kvalitéer ett 
effektivt immunsvar mot hiv behöver för 
att kontrollera virusproduktionen. Den 
enorma variationen som finns mellan 
olika hivvarianter och olikheten mellan 
människors HLA-molekyler gör det hela 
väldigt komplicerat att förstå. Men genom 
att samarbeta med bioinformatiker har vi 
i vår grupp kunnat ta hänsyn till dessa 
faktorer och identifierat hivsvar som är 
mer stabila och inte lika påverkbara av 
hivvariation och olikheter mellan HLA-
molekyler. I studien som publicerades i 
tidskriften Journal of Immunology (C. L 
Pérez et al, 2008) lyckades vi med hjälp 
av bioinformatiska modeller identifiera 
ett mindre antal hivfragment. Fördelen 
med dessa fragment är att de: 1) presente-
ras och känns igen i ett stort antal hivpo-
sitiva individer med ursprung från olika 
delar av världen och som uttryckte många 
olika HLA-molekyler, 2) känns igen av 
patienter infekterade med hivvarianter 
tillhörande många olika subtyper, och 3) 
är väldigt konserverade (ursprungliga) 
hos alla olika virusvarianter och subtyper. 
Det betyder att viruset troligtvis kommer 
att få svårt att fly från immunsvar som 
riktas mot dessa fragment och att de kom-
mer att kunna presenteras i många hivin-
fekterade individer trots att de är smittade 
med olika varianter av hiv. 
Hiv består av mer än 3 000 byggstenar, 
medan de fragment som presenteras på 
HLA-molekylen optimalt är nio byggste-
nar långa. Genom att på ett effektivt sätt 
skära ner på storleken av viruset och bara 
fokusera på de bitar som faktiskt kom-
mer att påverka immunsvaret gör vi det 
PPHIV 21   1320 10-06-16   15.03.51
PERSPEKTIV PÅ HIV NR 21/2010  1321
Att identifiera komponenter till ett optimerat hivvaccin
mycket lättare att studera immunsvaren 
mer detaljerat. Vi har på så sätt fått kun-
skap om hur hivfragmentets bindning till 
HLA-molekylen och T-cellens igenkän-
ning av detta HLA-hivfragment påverkas 
då viruset förändrar sitt utseende. Detta 
har gett oss värdefull information om hur 
det fungerar i kroppen när virus föränd-
rar utseende och hur pass tolerant im-
munförsvaret kan vara mot det. I en stu-
die som vi publicerade tidigare i år (I 
Hoof et al, J. Immunol, 2010) kunde vi se 
att immunsvaret är extremt känsligt för 
förändring och att även en väldigt liten 
förändring kan vara tillräckligt för att för-
störa igenkänningen hos T-cellen (Figur 
2). Men på de ställen där viruset inte kan 
ändra sig utan att förstöras kan det göra 
en slags kompromiss genom att bara för-
ändra sig väldigt lite för att bevara sin 
funktion. Trots att detta inte är tillräckligt 
för att fly undan immunförsvaret, blir 
svaret försvagat mot en sådan förändring 
och T-cellen kan inte agera lika kraftigt 
som den skulle ha gjort emot det ur-
sprungliga fragmentet som den tränats 
upp att känna igen. Det här kan ha stor 
betydelse för framtida vaccinframställ-
ning. Ett framtida vaccin skulle kunna 
baseras på just den här typen av kunskap 
för att veta exakt vad man vill lära im-
munförsvaret att känna igen. Dessutom 
skulle vaccinet, ifall man visste vilka för-
ändringar som vanligtvis sker, kunna lära 
immunförsvaret att även känna igen des-
sa och på så sätt kunna hantera en viss 
grad av virusvariation. 
Vad har vi oss att vänta i  
framtiden?
Trots att vi inte nått vårt mål ännu och 
fortfarande har en lång väg kvar till ett ef-
fektivt hivvaccin får vi inte glömma alla 
de framsteg som gjorts. Den snabba ut-
vecklingen av ny teknik gör det möjligt 
att söka och erhålla kunskap vi inte hade 
möjlighet till för bara några år sedan, då 
vi inte hade rätt verktyg och metoder för 
den typen av studier. Vår förhoppning är 
självklart att vi till slut ska kunna hitta ett 
sätt att överlista hiv och förhindra smitt-
spridningen. Men i dagsläget så är det 
fortfarande användandet av kondom som 
är det absolut mest effektiva sättet att 
undvika infektion vid sexuell smitta.
 Figur 2. Den hivspecifika T-cellen har svårt att känna igen fragment där en eller flera byggste-
nar har förändrats. Bilden visar att det räcker med att en av de nio byggstenarna (aminosy-
ror) som fragmentet består av förändras, så minskar möjligheten till T-cellsvar kraftigt. Om 
viruset har ändrat sig i fler än en aminosyra i fragmentet minskar möjligheten för svar ännu 
mera. (Bilden är omgjord från I. Hoof et al, J. Immunol, 2010.)
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